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Tuberculosis  (TB)  is an old disease  that was shown  to be present  in humans  thousands of 
years  ago.  The  bacterium  causing  this  disease,  Mycobacterium  tuberculosis  (MTB),  was 
discovered  in  1882  by  Robert  Koch.    MTB  is  a  highly  aerobic,  non‐motile,  pathogenic 
bacterium  from  the  family Mycobacteriaceae.  It  contains an unusual, waxy  coating on  its 
surface  made  from  mycolic  acid;  a  virulence  factor,  responsible  for  its  resistance  to 
desiccation. It is a slow dividing bacterium that divides every ~20 hours. MTB is part of the 
Mycobacterium  tuberculosis  complex  (MTBC),  a  family  consisting of at  least 9 genetically 




were  infected with MTB. Of those, 10 million people had  fallen  ill, with 1.3 million deaths 
within the human immunodeficiency virus (HIV) negative population and 0.3 million deaths 




20  to  37‐fold  [6].    An  efficacious  HIV  vaccine  would  therefore  be  able  to  reduce  aTB 
incidence rates in global regions with a high burden of HIV‐TB co‐infection. 
More adults  (90%) are  infected  than children and more men  than women, with a  ratio of 
male  to  female  of  approximately  2:1  [7].    The majority  of  the  disease  burden  seem  to 
concentrate within three regions; South‐East Asia (44%), Sub‐Saharan Africa (25%) and the 















the global TB epidemic by 2035. There  are  three main  indicators  for  this,  the number of 
deaths per year, the TB  incidence rate and the percentage of TB‐affected households that 
experience catastrophic costs as a result of TB disease. The main goal of this strategy  is to 
reduce TB death by 95%, while  reducing  incidence  rate by 90%, as compared  to  levels of 
2015, by 2035 [7].  
1.3‐ Pathophysiology 
Mycobacterium  tuberculosis  (MTB)  is  transferred  via  air  droplets  from  an  individual  that 
suffers  from  the  active  form  of  the  disease  (active  tuberculosis,  aTB)  to  another.  The 





disease  is usually  less  infectious when  it occurs  in  children, mostly due  to  them having a 
paucibacillary disease,  less  forceful cough and  less cavitary  lesions [9]. On the other hand, 
children are more vulnerable to the  infection and have a greater risk to progress to active 
disease once infection occurred, especially in children less than 5 years of age. 
The classic thought of the tuberculosis disease spectrum  is that  it exists  in two states, the 
metabolically  inactive form called  latent tuberculosis  infection (LTBI) and the metabolically 
active  form  called  active  tuberculosis.  It  is  assumed  that  5‐10%  of  all  LTBI  patients will 
develop  aTB,  especially  within  the  first  two  years  of  getting  infected.  However,  other 
situations may  increase the chances of one progressing to aTB, such as HIV co‐infection or 
other immunodeficient conditions; the reason being that CD4 T cells producing IFNγ play a 
crucial  role  in  controlling  MTB  and  thus  their  depletion  increases  the  likelihood  of 
progression  to  active  TB  [10,  11].  As  time  progressed,  scientists  gained  a  greater 
understanding about the disease pathophysiology and it has become clear that TB is, rather, 
a  continuous  disease  with  more  than  two  states  [12‐16].  In  order  to  understand  the 
pathophysiology  better,  scientists  have  added  three  additional  groups;  eliminated  TB 
infection, incipient TB infection and subclinical TB infection [17]. Elimination of TB infection 
occurs when an  individual  gets exposed  to  viable MTB  and his  innate/adaptive  immunity 
clears  the  infection.  LTBI occurs when a healthy person gets exposed  to MTB, but  rather 
than eliminating it, the immune system controls it reducing the likelihood of aTB occurring. 
This  is performed by  immune cells such as CD4 T cells which release cytokines that attract 
neutrophils and macrophages, surrounding  the bacteria and  isolating  it  in what  is called a 
granuloma.  The  CD4  T  cells  are  crucial  for  granuloma  formation  as  they  maintain  its 
organization [18].  Incipient TB  infection  is an  infection that  is  likely to cause aTB, however 
no signs appear radiologically or microbiologically to suggest such an event from occurring.  
During subclinical TB,  the bacterium causes asymptomatic disease, which can be detected 
radiologically  or  microbiologically.  Finally,  during  active  TB  the  disease  causes  clinical 
symptoms that can also be radiologically and microbiologically detected [17].  
Following the establishment of LTBI an individual has several pathways by which the disease 






person.  Lastly,  the  disease  may  cycle  between  incipient  and  subclinical  disease,  before 
either getting eliminated, or developing active TB (Figure 1.3). It is clear that, although LTBI 








One  of  the  first  drugs  to  be  developed  for  anti‐tuberculosis  therapy  (TB)  was  PAS  (4‐
aminosalicylic acid), back  in 1943  [20]. This was  followed by the discovery of the effect of 
streptomycin  against  Mycobacterium  tuberculosis  by  Selman  Waksman  in  1944  [21]. 
However,  this drug had  to be  injected  and had  serious  side  effects  such  as hearing  loss. 
Finally  in  1951,  isoniazid  was  discovered  by  three  pharmaceutical  companies;  this 
compound was found to be 10 times more potent than its predecessors. By then people had 







The  current  standard  anti‐TB  therapy  for new patients with drug‐susceptible  tuberculosis 







no  resistance  is  documented,  the  standard  therapy  can  be  applied  again,  however  if 
resistance  occurs,  then  treatment  must  be  changed  and  lengthened  depending  on  the 
resistance  observed,  whether  it  is  multi‐drug  resistance  (MDR‐TB)  or  extensively  drug 
resistant (XDR‐TB) (Figure 1.4) . 
The problems that arise with a “one‐size‐fits‐all” approach to standard therapy are that the 
patient may  suffer  from physiological conditions, such as hepatotoxicity,  liver  toxicity and 
neurological  disorders  [27,  28].  This  leads  to  non‐compliance  from  the  patient  and  the 
development  of  resistant mycobacterial  strains,  which  eventually  results  in  even  longer 
treatment  durations.  Several  studies  have  tried  to  reduce  the  treatment  period  for  TB 
therapy. Previous  studies, consisting of 2  randomized control  studies and 2 observational 




consisting  of  3  phase  3  trials  using  fluoroquinolones,  gatifloxacin  and moxifloxacin,  have 
tried  to  reduce  therapy  from  6  to  4  months  for  drug‐susceptible  tuberculosis  [34‐37]. 
Although,  the majority of  the patients  (80%) had been cured after 4 months without any 
relapse after a  follow up of 18 months,  the  relapse  rate was higher  than  in  the  standard 
therapy and thus declared unsuccessful. Currently, a study called SHINE (shorter treatment 






Figure  1.4:  Treatment  strategy  towards  Pulmonary  Tuberculosis  (PTB).  Anti‐TB  therapy 
requires 6 month of treatment where 4 drugs are used during the first 2 months (intensive 
phase)  followed by 2 drugs  for 4 months  (continuation phase). A  follow up period ensues 
after  end of  treatment.  If  relapse were  to occur, drug  susceptibility  is performed on  the 







is suspected. The health worker can examine the  lungs  in this manner and thus see  if any 







The Mantoux  tuberculin skin  test  is  the process by which one  tests whether an  individual 
has  been  infected  with  Mycobacterium  tuberculosis  or  not.  It  is  one  of  the  earliest 
techniques  developed  in  the  19th  century  that  is  still  in  use.  The  procedure  involves  the 
intradermal  injection of tuberculin purified protein derivative (PPD)  into the  inner forearm 
of a person. After 48 hours  the person  comes back  in order  to determine  the  results, by 
measuring the diameter of the swelling. The reasoning that underlines this process is that T 
cells are  sensitized  towards  tuberculin by prior  infection. Thus, a delayed hypersensitivity 
reaction occurs after the  injection, where T cells are recruited to the site and release their 
cytokines causing an  inflammatory  reaction. The Mendel‐Mantoux  test only measures  the 
hypersensitivity towards tuberculin and not TB  immunity. One of the disadvantages of this 
test  is  that BCG‐vaccinated  individuals could also provide a positive  result  (false positive). 
Furthermore, one can not determine whether a subject has active TB or not. False negative 
results  could be provided by  infants and  those only  recently  infected by  tuberculosis and 
lastly, the technique itself requires trained personal [39].  
1.5.3‐ Acid‐Fast Bacilli (AFB) smear microscopy 
Acid‐Fast  Bacilli  smear  is  a  microscopic  process  where  a  sample  is  stained  with  a 
flurochrome  in order to detect Mycobacteria. If mycobacteria (acid‐fast bacilli) are present 
in the sample they will be seen under the microscope  following an acid wash due to their 
ability  to  resist  decolourization  via  the  mycolic  acid  in  the  cell  wall  thus  retaining  the 
primary stain.  The advantages of this technique are that it is a rapid, inexpensive and easy 
procedure, where different  types of  specimen  can be  tested  (tissue,  sputum, body  fluids, 
etc.)  [40]. Furthermore,  it could be used as a  first  indication of a mycobacterial  infection; 











or  liquid medium.  It  is currently the gold standard for sensitivity and specificity and unlike 
the  smear method  can  be  used  for  species  identification  and  drug  susceptibility  testing 
(DST). Furthermore, although not optimal, it is used for monitoring TB treatment response. 
Both the  liquid and solid medium are recommended for use. The solid medium consists of 
two  methods,  one  is  the  Lowenstein‐Jensen  (LJ,  egg  based)  and  the  other  is  the 
Middlebrook  7H10  (M7H10,  agar  based).  Each  one  has  its  own  advantages  and 
disadvantages, with the M7H10 medium allowing faster culture growth and allowing easier 
colony quantification, while the LJ suffers from less contamination. Liquid medium although 
even  easier  to  contaminate  than  the  solid medium,  can  provide  fast  detection  time  of 
mycobacteria. Although, used in tuberculosis diagnosis, the method is far from perfect; their 
reliance  on  sputum, which  is  obtained  from  non‐sterile  regions,  leads  to  contamination 
issues  [43]. Furthermore,  it  is difficult  to obtain  sputum  from  infants  [44].  False negative 
arises in paucibacillary aTB patients and those where aTB lesions do not have access to the 
airways,  for  example  in  extra‐pulmonary  TB  patients  [45,  46].  MTB  cultures  have  low 




IGRA  is used  to detect  the  immune  response  towards Mycobacterium  tuberculosis  (MTB). 
The method relies on the fact that most people, who have been previously exposed to MTB, 
produce  specific  immune  cells  that  upon  re‐exposure  to  that  antigen  produce  interferon 
gamma (IFNγ). There are two ways for measuring this marker and that is either by enzyme‐
linked immunosorbent assay (ELISA, QuantiFERON assays) or via enzyme‐linked immunospot 










use  of  the  early  secretory  antigenic  target  (ESAT)‐6/  culture  filtrate  protein  (CFP)‐10 
antigens  that  are  specific  to  the MTB.  Thus,  individuals who  had  taken  the  BCG  vaccine 
(false positive in the TST) would not obtain any result in the IGRA assays. However, similar to 
the  TST,  both  techniques  suffer  from  poor  sensitivity  (~80%)  and  can  not  differentiate 
between  active  TB  and  LTBI,  even  when  using  a  different  marker  such  as  interferon  γ 
inducible  protein  (IP‐10)  [49‐52].  Unlike  the  TST  though,  the  techniques  have  a  higher 
specificity  (~90% vs. ~60%)  [53]. Furthermore  it  is believed  that QuantiFERON assays may 
not  be  beneficial  for  HIV  infected  individuals.  Lastly,  its  requirement  of  a  lab  makes  it 
impossible for its use as a point of care diagnostic technique. 
1.5.6‐ GeneXpert MTB/RIF  
The GeneXpert  is a new, nucleic acid amplification TB diagnostic  technique  that works by 
measuring  the  deoxyribonucleic  acid  (DNA)  of  the Mycobacterium  tuberculosis  complex 
(MTBC) within a sputum sample via PCR [54]. The process takes less than 2 hours and has an 
additional benefit of measuring the genetic mutations associated with resistance to the drug 
rifampicin. The process  is  fully automated and  thus minimal  technical  training  is  required. 
However,  since  it  measures  the  DNA  of  MTBC,  it  suffers  from  a  lag  during  treatment 
monitoring  and detection of  end of  treatment,  as  it  can not differentiate  live  from dead 
bacilli  [55]. As other  sputum dependent diagnostic  techniques  it has  a poor  sensitivity  in 
detecting certain extra‐pulmonary tuberculosis [56].  
Figure 1.5: Tuberculosis Pathophysiology in comparison to current diagnostic tools in use. 







As mentioned above, several of  the current diagnostic  tests suffer  from  lack of sensitivity 
and  thus  fail  to  differentiate  active  tuberculosis  (aTB)  from  latent  TB  infection  (LTBI). 




coming  from  the dormancy of  survival  regulon  (DosR), which  consists of genes expressed 
during latency. One of the antigens that show promise is the Heparin‐Binding Hemagglutinin 
(HBHA), which  induces  the  production  of  IFNγ  by  cells when  the  bacterium  is  contained 
(LTBI), while during aTB no IFNγ is produced [57‐59]. Although promising, the antigen does 
seem  to  have  shortcomings when  it  comes  to HIV  co‐infection, where HIV‐LTBI  patients 
seem  to  produce  low  IFNγ  response  [60,  61].  Furthermore,  children  that  suffered  from 





Measuring  soluble  cytokine  levels within  the blood of aTB,  LTBI  and healthy  control  (HC) 
patients as a method to discriminate between these different states has also been explored. 
Some  studies  use  unstimulated  whole  blood,  which  renders  the  plasma  markers 
concentration observed not  specific;  since  the  change observed might not necessarily be 
due to tuberculosis, but an underlying factor or disease. Some studies do look at stimulated 
whole blood, however several markers, such as macrophage inflammatory protein (Mip)‐1β, 
C‐Reactive  Protein  (CRP),  IFNγ,  interleukin  (IL)  ‐2,  IL‐10,  IL‐12,  IL‐17  interferon  gamma 
inducible  protein  ‐10  (IP‐10)  and  RANTES  (Regulated  upon  Activation,  Normal  T  cell 
Expressed,  and  Secreted)  were  not  able  to  discriminate  between  aTB  and  LTBI  [63‐67]. 
Similar  results  (no  difference) were  observed  for  some  of  the markers when  used  in  TB 
treatment monitoring [68]. However, markers such as IP‐10, may be useful at discriminating 
between  those  that  were  exposed  to  MTB  (aTB  and  LTBI)  and  healthy  controls  [67]. 
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Although,  on  their  own,  each  marker  may  not  be  able  to  differentiate  aTB  from  LTBI, 
different approaches where one may utilize  combinations  to obtain better  results  can be 




Genome  wide  RNA  expression  profile  is  a  new  tool  that  provides  information  on  the 
response  from  the host  towards Mycobacteria  tuberculosis  [71]. The process  involves  the 
extraction  of  RNA  from  unstimulated  whole  blood  or  PBMCs  and  performing  next 
generation  sequencing  and  big  data  analysis  to  identify  which  genes  are  up‐  or 
downregulated within an individual. Although, still in its infancy, the technique has provided 




within  the  first  two  weeks  of  anti‐TB  chemotherapy,  and  continued  to  decrease  as 
treatment progressed to 6 months [74]. One of the issues with the transcriptomics studies is 
that  they  rely on unstimulated whole blood, questioning whether  the genes detected are 
specific to tuberculosis or not. Another study by Bloom et al. and Kaforou et al. were able to 
show that certain gene signatures were able to discriminate between an individual infected 
with  tuberculosis  or  other  diseases,  such  as  pneumonias,  lung  cancers  pulmonary 
sarcoidosis and HIV [73, 75]. In general, RNA expression profiling is regarded as a powerful 
way  to understand and diagnose diseases and  to elucidate  immunological processes  [71]. 







datasets  from  several  previous  studies  containing  a  heterogeneous  population  with 
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with  a  sensitivity  of  66.1%  and  a  specificity  of  80.6%  12 months  preceding  tuberculosis 
diagnosis. Due to this poor sensitivity, the genes would most probably be used  in high risk 
settings and  to predict  those  individuals who have a high chance of not developing active 
TB. Recent studies try to look at genes within certain cell populations in whole blood such as 
CD4+ T cells to try and obtain further insight into the function and phenotype within these 
populations  [80]. One  of  the  issues with  the  transcriptional  studies  is  the  computational 
methods  used  for  each  study  differs  than  the  rest,  in  other  words  the  computational 
landscape is still developing and thus there is little overlap in the genes discovered between 












phenotypic  changes  are  a  reflection  to  changes  in  T  cell  function  as  a  consequence  to 
different disease status. The rarity of the CD8 T cell response to PPD, especially within the 
LTBI population, made it difficult to be incorporated into this assay [83‐87].  
The  first marker  to  be  used  in  the  TAM‐TB  assay  is  CD27.  This  “maturation” marker,  a 
member of the TNF‐receptor superfamily and  involved  in co‐stimulation,  is downregulated 
as  a  T  cell  changes  from  a  naïve  (antigen  inexperienced)  to  a  memory  T  cell  (antigen 
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and  latent  TB,  it  can’t  be  used  to monitor  or  to  determine  end  of  TB  therapy.  Further 
evidence for the use of CD27 as a marker for TB diagnostic was buttressed by Schuetz et al., 
where  the  observed  phenotypic  changes  in  the  MTB‐specific  CD27  cells  was  observed 
regardless of HIV infection status [92], this was also confirmed by Riou et al. [85]. However, 








shown  that  the  accumulation  of  these  MTB‐specific  IFNγ+  producing  CD27‐  cells  in 
peripheral blood,  correlated with  factors  such as  lung destruction and  clinical TB  severity 
[93].  In addition, although CD27‐  reverts slowly,  for  those  subjects  that did  show a  faster 
decline in CD27‐ cells with treatment progression, the aforementioned symptoms decreased 
[93]. A recent prospective cohort study was performed on paediatric children, using CD27 as 
a diagnostic marker  for active TB. Although,  rather  than  relying on  the % of MTB‐specific 
CD27 cells, they looked at the mean fluorescent intensity (MFI). This method was compared 
with the culture method and the Xpert MTB/RIF assay [94]. Portevin et al.  was able to show 
that  in a  sample  size of 113, a  sensitivity of 83.3% and  specificity of 96.8% was achieved 
using the MFI [94]. Of interest though, is the fact that the TAM‐TB assay was able to detect 8 






and  shown  that  those  subjects with a more persistent culture positivity and X‐ray  lesions 
seem  to  have  a  stronger  CD27  expression.  Although,  the  definition  of  persistent  TB  is 
different from each paper, with one describing culture positivity after at  least 6 months of 
standard TB therapy [95] and the other, after 2 months of therapy [96].  
The  next  promising  markers  to  be  used  in  the  assay  are  2  activation  markers  and  a 
proliferation marker;  CD38,  a  transmembrane  glycoprotein  involved  in  the  catalysis  and 




from  LTBI  [84]. All  three markers  showed an  activated phenotype during  active TB  (% of 
MTB‐specific CD38+, HLA‐DR+, Ki67+ CD4+ T cells), while LTBI subjects had a downregulation 




within  the  first  two months  after  treatment  initiation,  while  HLA‐DR  showed  a  gradual 
decrease. Unlike CD27, which required a  long duration of time after TB treatment  in order 
to  revert  to  its pre‐TB  infected phenotype,  these  three markers were able  to achieve  the 
LTBI phenotype within the treatment window. Thus, these markers would be better suited 
for  treatment  monitoring.    A  correspondence  by  Wilkinson  et  al.  has  examined  these 
markers and their ability to differentiate active TB from LTBI within a population co‐infected 
with  HIV  [98].  Although  similar  phenotypes  were  observed  for  active  and  LTBI  for  the 
frequencies  of  all  three markers  on  ESAT‐6/CFP‐10  stimulated  IFNγ+ MTB‐specific  CD4  T 
cells, Ki67 and   CD38 performed poorer  in the TB+/HIV+ group. A reason behind this could 











recent  study  agrees with  the  results observed  for  the CCR4 marker on  ESAT‐6/CFP‐10,  it 
does show a significant difference for PPD stimulated cells (not tested by Riou et al.) [99]. 
Latorre et al. tests both CD27 and CCR4 on CD4+ IFNγ+ cells and goes a further step by using 
both  concomitantly  to  try  and  decrease marker  overlap  between  active  TB  patients  and 
LTBI. Nevertheless, using CD27 alone was able to show a similar sensitivity and specificity as 
in  combination  [99].  Although  the  other  two  markers  (CXCR3  and  CCR6)  failed  to 
differentiate between active TB and LTBI, CXCR3+CCR6‐ CD4+ T cells did present themselves 






contacts.  However,  by  calculating  a  score,  where  the  %CD4+/CD8+/CD3+  CD161+  is 
multiplied  against  the  lymphocyte  to monocyte  ratio,  a  better  sensitivity  and  specificity 
value was obtained; with CD8+ CD161+ showing the best values. One of the issues with this 
study  is  the  use  of  unstimulated  whole  blood  and  thus  the  specificity  of  the  change 
observed in the marker might occur with other diseases and not just during Mycobacterium 
tuberculosis (MTB)  infection [101]. However, Riou et al. has shown that at  least with ESAT‐
6/CFP‐10  stimulated  cells,  no  difference was  observed  for  the %frequency  of  CD161  on 
IFNγ+ cells [85].  







did  show  a  significant  difference  between  active  TB  and  LTBI,  this  difference  was  only 
observed on CD8+ IFNγ+ cells. This poses a difficulty due to the low IFNγ secretion in CD8 T 
cells.  






an  initial  positive  culture.  Henceforth,  although  this  marker  may  not  be  beneficial  in 
differentiating active TB from LTBI, it could be used to determine those that might need to 
undergo  longer  duration  of  treatment  due  to  standard  anti‐TB  chemotherapy  failure. 
Another paper by Saharia et al. showed  that  for PPD stimulated cells,  the %  frequency of 
CD244  cells  did  not  show  a  significant  difference  between  treated  and  untreated  TB, 
although  a  downregulation  was  observed  as  treatment  progressed  [103].  However,  for 
those individuals co‐infected with HIV, there was a significant upregulation in CD244 specific 
CD4 T cells as anti‐TB  therapy progressed.   Hence, HIV could play a disruptive  role  in  this 
marker being used for treatment failure or success. The only issue with this study is the low 
number of individuals tested for each group (n < 12). 
PD‐1,  an  inhibitory  receptor, was  shown  by  Adekambi  et  al.  to  be  upregulated  on  LTBI 











Intracellular cytokines have also  shown  their  importance  for use as diagnostic  tools, even 
though IFNγ+ MTB‐specific CD4+ T cells alone were not sufficient to diagnose aTB (as shown 
in IGRA) [85]. However, a combination of three cytokines (IL‐2, IFNγ and TNF‐α) may play a 
more  beneficial  role.  The  issue  that  arises  with  such  studies  is  the  conflicting  results 


































Rv144  vaccine  consisted  of  4  injections with  a  recombinant  Canarypox  viral  vector  that 





embedded  case‐control  study  showed  that  strong  IgG  recognition  of  the  HIV  Envelope 
protein  variable  region  2  correlated  with  a  reduced  risk  of  HIV  acquisition  [108]. 
Furthermore, fine mapping of vaccine‐induced IgG Envelope recognition by a peptide array 
approach  identified a 15 amino acid  long  region  located  in close proximity  to  the HIV co‐
receptor  α4β7  Integrin  (representative  peptide  sequence;  TELRDKKQRVYALFY)  [109].  















In  this  publication  we  present  how  the  TAM‐TB  markers,  on  MTB‐specific  CD4  T  cells, 
change as TB  treatment progresses. Furthermore, not all markers are  required  for  future 
studies  as  some  show  redundancy  in  results.  Lastly,  the  change  in %frequency  on MTB‐
specific  CD4  T  cells  correlate with  the  time  to  stable  culture  conversion.  In  this  study  I 
performed the assay itself, starting from thawing the PBMCs, stimulating the cells overnight, 




In  this  publication  we  compare  the  immunologic  response  in  participants  taking  two 
different  vaccine  strategies.  I  contributed  to  the  peptide  array  experimental work,  data 
analysis, generating the graphs and article figures.  
Publication 3 (Ahmed et al. 2019) 
In  this  publication  we  present  how  the  TAM‐TB  assay  may  be  used  for  TB  treatment 
monitoring on an  individual suffering  from an extra‐pulmonary TB  (hip TB).  In  this study  I 
performed  the  TAM‐TB  assay,  from  isolating  the  PBMCs,  stimulating  the  cells  overnight, 










We  have  shown  that  current  diagnostic  tools,  although  effective  in  combination  at 
recognizing  symptomatic  tuberculosis,  still  lack  in  several  aspects  when  it  comes  to  TB 
treatment,  such  as  determining  the  end  of  treatment,  monitoring  therapy,  diagnosing 
asymptomatic  and  extra‐pulmonary  TB  (especially  in  children)  and  determining 
prospectively who from the LTBI patients would most likely develop aTB. These issues arise 




lag  in  positivity, mainly  due  to  its  recognition  of  dead  bacilli, while  the  sputum  culture 
method has a low sensitivity and positive predictive value estimate [55]. Techniques such as 
the  sputum  culture  also  suffer  from  the  length  required  to achieve  results.  Furthermore, 
sequential sputum bacterial load measurement by culture showed insufficient sensitivity for 
detecting  unfavorable  outcomes  [47].  The  IGRA  test  was  shown  to  lack  the  ability  to 
distinguish  aTB  from  LTBI  rendering  it  useless  for  TB diagnosis  and monitoring. All  these 
issues impede the accurate diagnosis of TB leading to a presumptive diagnosis.  
Several studies have shown that a high percentage of patients are cured before the 6 month 
standard  therapy  [34‐36].  A  blood  based  immunodiagnostic  technique,  called  the  T  cell 
activation marker assay  (TAM), was developed  to  try and overcome  the current problems 




active  TB,  the  activation  and  proliferation  markers  are  upregulated  on  MTB‐specific 
CD4+IFNγ+ T cells, while the maturation marker is downregulated. In addition, evidence has 





order  to  further  characterize  the  different  TB  infection  stages:  active  TB,  “cured”  TB  (6 
months after treatment initiation) and LTBI (table 1). Furthermore, information still lacks on 
how  the  change  in  markers  as  treatment  progresses  correlates  with  the  in  vivo 
mycobacterial load. 
The  purpose  of  this  study,  as  stated  in  our  article  “is  to  obtain  a  more  detailed 
understanding of the relationship between TAM‐TB assay results, the MTB infection status, 
and mycobacterial  treatment  response. Here, we have  therefore  studied activation  (CD38 















The UKHVC  SPOKE03  trial  compared  two  different  prime‐boost  vaccination  strategies  as 
follows; the standard group first received 3 vaccinations of HIV‐DNA followed by two boosts 
of  Modified  vaccinia  virus  Ankara  (MVA)‐C  and  an  additional  two  boosts  with  the 
recombinant protein CN54gp140  in 5ug of the novel adjuvant GLA‐AF  [2]. The accelerated 





















Childhood  tuberculosis  is  very difficult  to diagnose due  to  the  child’s  inability  to produce 
sputum  easily  (especially  infants).  Furthermore,  children  usually  suffer  from  the 
paucibacillary  form of the disease, rendering several diagnostic tools  ineffective. A  further 
complication  more  frequently  observed  in  younger  children  as  well  as  in 
immunocompromised patients,  is  the extra‐pulmonary  (EPTB)  form of  the disease. Due  to 
the assays nature of indirectly diagnosing active TB, it may be likely that the TAM‐TB could 
be  a  very  useful  tool  for  EPTB  situations.  However,  it  is  unknown whether  this  form  of 
tuberculosis would also render the TAM‐TB assay ineffective or not. It has been shown that 
markers  such  as CD27 present  in peripheral blood have been  correlated with  lung  tissue 
damage,  this may  not  necessarily  be  indicative  that  other  forms  of  TB  produce  similar 
results. This  is especially  true  for EPTB,  since  some  forms have a  farther proximity  to  the 
circulatory system than the lungs.  

















Diagnostic  tools  such  as  the  tuberculin  skin  test  (TST),  acid  fast  bacilli  (AFB)  smear 
microscopy  method,  the  sputum  culture  method,  the  interferon  gamma  release  assay 
(IGRA) and the GeneXpert are currently used in combination to diagnose TB and determine 
treatment  outcome.    Techniques  such  as  the  TST  and  IGRA,  which  detect  the  immune 
response towards the bacterium, are quick methods that determine whether an  individual 
was  infected with MTB, with the  IGRA being more specific. However these techniques are 
unable  to differentiate aTB  from LTBI,  thus  rather used as an aid  for diagnosing MTB. For 
unvaccinated children below the age of 5, the TST has a superior sensitivity than the  IGRA 




culture method  is  the  only method  available  to monitor  treatment  response  during  TB 
therapy. However, it suffers from the extended time period required to obtain results, high 
contamination  rate  due  to  its  reliance  on  sputum  and  false  negatives  observed  in 
paucibacillery aTB and cases where the lesions do not have access to the airways [43, 44, 46, 
113].  Furthermore,  sequential  sputum  bacterial  load  measurement  by  culture  showed 
insufficient sensitivity for detecting unfavorable outcomes [47]. The GeneXpert technique is 




negative  patients  (64%  vs  46%)  as  compared  to  its  predecessor  GeneXpert,  although 
showing a slight decrease in specificity [114, 115]. This technique however, suffers when  it 
comes  to monitoring  treatment  efficacy  due  to  its  lag  in  positivity,  the  reason  being  its 
detection of dead bacilli [55]. Thus, in conclusion the diagnosis of a patient is usually based 
on a presumptive basis [116].  
The  T  cell  activation marker  assay  is  a  sputum  independent whole  blood  technique  that 
depends on  the phenotypic  changes  that occur on MTB‐specific CD4  T  cells.  It  is  a  rapid 
assay  that  requires  a  single  day  to  process  the  results.  It  contains  a maturation marker 
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the  maturation  marker  was  high.    Furthermore,  we  were  able  to  show  a  substantial 
reduction  in  the %frequency  of  activation  (CD38  and  HLA‐DR)  and  proliferation markers 
(Ki67) on MTB‐specific CD4 T cells within  the  first  few weeks of  treatment  initiation. This, 
however, was not true for the maturation marker (CD27) throughout the treatment period 
(26 weeks)  in PTB. While  in EPTB, a gradual  increase was observed albeit slower  than  the 
other markers. These changes observed, due  to  tuberculosis  therapy, were specific  to  the 
MTB‐specific compartment, since the same markers on total CD4 T cells did not show any 
difference  as  compared  to  the  pretreatment  status.  A  plausible  reason  behind  this  slow 
CD27  reversion  could be  the  residual TB disease  activity at  the end of TB  treatment  and 





from  LTBI  in  PTB  and  correlated  with  the  activation  (HLA‐DR)  and  proliferation  (Ki67) 









CD4  T  cells. However,  for  EPTB,  the  fact  that  only  one  patient was  involved makes  this 
conclusion  less  concrete,  since a gradual  increase  in  the %frequency of  the CD27 marker 
into  the  LTBI  range was  observed.  The  reason  behind  this  could  be  that  the  treatment 
period  for  EPTB  is 12 month  as  compared  to  the  standard  therapy  for PTB of 6 months, 
allowing more  time  for  CD27  to  revert  [111].  Another  reason might  be  that  the  patient 
responded well  to  treatment,  so  one  could  argue  that  he  could  have  potentially  discontinued 




standard  therapy  for pulmonary  tuberculosis  is 6 months, while  that  for extra‐pulmonary 
tuberculosis may range from 9‐12 months. This hampers compliance and may also  lead to 
psychological  and  physiological  side  effects  as  well  as  financial  burden  on  the  patient. 
Furthermore,  the  premature  discontinuation  of  the  treatment  may  lead  to  the  rise  of 
resistant  forms  of  the  bacterium.  Several  studies  have  tried  to  address  this  issue,  albeit 
unsuccessful  due  to  the  high  relapse  in  the  shorter  treatment  therapy  [34‐36].    Current 
diagnostic tools such as the IGRA, TST, GeneXpert and even the gold standard, the sputum 
culture method,  fail  to monitor TB  treatment and determine end of  treatment. Thus, we 
tried  to  obtain  a  greater  understanding  at  how  our  markers  may  be  influenced  by 
mycobacterial  load  by  comparing  our method with  the  sputum  culture method. Weekly 
culture results were available for the first 12 weeks, followed by cultures at week 14, 17, 22 




negative  samples), were  less  than  or  equal  to  4 weeks.  Initially,  single  time‐points,  post 
treatment  initiation,  were  used  to  determine  the  end  of  treatment.  Individuals  that 
responded well  to  treatment  and  could  supposedly  could  end  treatment  early would  be 
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below  a  pre‐defined  cut‐off  for  a  specific  marker,  while  those  that  had  to  continue 
treatment, would have a % marker  frequency above  that  cut‐off; however no  correlation 








in  the  plasma  of  aTB  patients,  the  determination  of  RNA  expression  profile  of  different 
disease  states  (transcriptomics)  and  the  identification  of  novel  antigens  that  can 
differentiate aTB  from  LTBI, although  interesting with promising  results, have unavailable 
data  when  it  comes  to  TB  treatment  monitoring.  In  addition,  genes  identified  via  the 
transcriptomic method, need  to be processed  into  simpler  tests,  such as PCR,  in order  to 
avoid the sophisticated resources required for these tests.  
Current  limitations  in our study  (Ahmed et al. 2018)  involved  the  lack of X‐ray scores and 
disease  severity assessment,  such as  the number of  lesions  in  the  lungs, available  for  the 
pulmonary TB patients. Although, a high proportion of TB patients are co‐infected with HIV, 
our cohorts did not include any of these patients and thus the effect of HIV on the TAM‐TB 




look  promising,  the  study  still  represents  a  single  patient  for  a  heterogeneous  group  of 
diseases. Furthermore, the cut‐off values of the markers on MTB‐specific CD4 T cells  from 
the EPTB patient were referenced to PTB patients and thus, modifications need to be made 




Although  the  TAM‐TB  assay  has  several  benefits,  it  remains  an  expensive  and  complex 
technique requiring specialized  instrumentation and  trained personal  to operate. Thus,  its 
use as a point of care diagnostic technique and  in resource poor settings may be difficult. 
Rather,  it  could be  incorporated  in  reference  laboratories. Current  studies  are  looking  at 
simplifying  the assay, by using whole blood  instead of peripheral blood mononuclear cells 
[121].  This  would  be  especially  important  for  vulnerable  patients  such  as  infants  and 
children,  as  it  reduces  the  volume  of  blood  required  to  be  drawn.  Recently,  in  order  to 
reduce and simplify the steps required to process the samples thus reducing the hands on 
time  required by  the personal, we  further developed our whole blood TAM‐TB assay. By 
using whole blood  instead of PBMCs we were able  to avoid  the  long process of  isolating 
these cells. Secondly, we developed two pre‐prepared lyophilized tubes, one containing our 
stimulating  peptides  and  the  other  containing  the  antibodies  for  the  surface  and 
intracellularly  antigens we would  like  to  stain.  From our  results  (Ahmed  et  al. 2018), we 
were able to reduce the number of markers required in the assay, thus limiting the number 












vaccines  that  induce  strong HIV Env‐specific  IgG  recognition of  the variable  regions 2 and 
also 3 are good candidates to be tested  in expensive phase 3 HIV vaccine trials. During the 
Spoke03  trial,  the  recognition of  linear HIV envelope  regions by  IgG  for  the  standard and 












in  the  gp120 monomer,  but may  be  occluded  in  the  trimeric  Envelope  protein, which  is 
present on the infectious HIV virion [123]. Further studies also showed that IgG recognition 
of the V3 region was broadly cross‐reactive. These are promising results, as IgG recognition 














































































































































































































































































































































[1]  Ahmed MIM, Ntinginya NE,  Kibiki G, Mtafya  BA,  Semvua  H, Mpagama  S, Mtabho  C, 
Saathoff E, Held K, Loose R, Kroidl I, Chachage M, von Both U, Haule A, Mekota A‐M, Boeree 
MJ, Gillespie SH, Hoelscher M, Heinrich N and Geldmacher C (2018) Phenotypic Changes on 




DJM,  Tatoud R, Wagner R,  Esteban M,  Shattock RJ, McCormack  S  and Weber  J  (2017) A 








published: 28 September 2018
doi: 10.3389/fimmu.2018.02247
Frontiers in Immunology | www.frontiersin.org 1 September 2018 | Volume 9 | Article 2247
Edited by:
Heinrich Korner,
University of Tasmania, Australia
Reviewed by:
Ronan O’Toole,
University of Tasmania, Australia
Florian Kern,







†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology
Received: 17 April 2018
Accepted: 10 September 2018
Published: 28 September 2018
Citation:
Ahmed MIM, Ntinginya NE, Kibiki G,
Mtafya BA, Semvua H, Mpagama S,
Mtabho C, Saathoff E, Held K, Loose
R, Kroidl I, Chachage M, von Both U,
Haule A, Mekota A-M, Boeree MJ,
Gillespie SH, Hoelscher M, Heinrich N
and Geldmacher C (2018) Phenotypic
Changes on Mycobacterium
Tuberculosis-Specific CD4T Cells as






Tuberculosis-Specific CD4T Cells as
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Background: The analysis of phenotypic characteristics onMycobacterium tuberculosis
(MTB)-specific T cells is a promising approach for the diagnosis of active tuberculosis
(aTB) and for monitoring treatment success. We therefore studied phenotypic changes
on MTB-specific CD4T cells upon anti-tuberculosis treatment initiation in relation to the
treatment response as determined by sputum culture.
Methods: Peripheral blood mononuclear cells from subjects with latent MTB infection
(n = 16) and aTB (n = 39) at baseline, weeks 9, 12, and 26 (end of treatment) were
analyzed after intracellular interferon gamma staining and overnight stimulation with
tuberculin. Liquid sputum cultures were performed weekly until week 12 and during 4
visits until week 26.
Results: T cell activation marker expression on MTB-specific CD4T cells differed
significantly between subjects with aTB and latent MTB infection with no overlap
for the frequencies of CD38pos and Ki67pos cells (both p < 0.0001). At 9 weeks
after anti-TB treatment initiation the frequencies of activation marker (CD38, HLA-DR,
Ki67) positive MTB-specific, but not total CD4T cells, were significantly reduced
(p < 0.0001). Treatment induced phenotypic changes from baseline until week 9 and
until week 12 differed substantially between individual aTB patients and correlated with
an individual’s time to stable sputum culture conversion for expression of CD38 and
HLA-DR (both p< 0.05). In contrast, the frequencies of maturation marker CD27 positive
MTB-specific CD4T cells remained largely unchanged until week 26 and significantly
differed between subjects with treated TB disease and latent MTB infection (p= 0.0003).
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Discussion: Phenotypic changes of MTB-specific T cells are potential surrogate
markers for tuberculosis treatment efficacy and can help to discriminate between aTB
(profile: CD38pos, CD27low), treated TB (CD38neg, CD27low), and latent MTB infection
(CD38neg, CD27high).
Keywords: TAM-TB assay, tuberculosis, treatment monitoring, Mycobacterium tuberculosis-specific T cells, serial
sputum culture, biomarker
INTRODUCTION
Novel diagnostic tools for improved detection of active
tuberculosis (aTB) and for monitoring TB treatment are urgently
required to succeed in the WHO END TB strategy, which—
in the abscence of an efficacious MTB vaccine - sets the
ambitious target of a world free of tuberculosis by 2030 (1).
Recent studies have highlighted the diagnostic potential of a
flow cytometry based approach to detect and differentiate aTB
disease from latent Mycobacterium tuberculosis (MTB) infection
(LTBI) via phenotypic and/or functional characterization of
MTB-specific T cells in adults and children (2–12). These “T cell
activation and maturation marker assays” (TAM-TB assay) are
sputum-independent, use easy-to-collect peripheral blood and—
in contrast to the traditional immunodiagnostic Tuberculin
skin test or Interferon gamma release assays (13)—allow highly
specific detection of aTB (3, 5). TAM-TB assay results have
been correlated with MTB loads in sputum (4, 9), with disease
severity and with lung tissue destruction (4). Our previous study
showed highly specific detection of childhood aTB in an endemic
setting (3), potentially superior to sputum culture. Furthermore,
TB treatment initiation decreases activation marker expression
on MTB-specific CD4T cells, probably reflecting the decrease
of mycobacterial burden in vivo (5); which would make this a
promising candidate marker for assessing TB treatment success.
While liquid culture and PCR are held to be the most
sensitive tools to detect MTB, their widespread implementation
for diagnosis and treatment monitoring is hampered by practical
and methodological problems. Firstly, since these methods
function by direct detection of the pathogen, they often remain
false negative in paucibacillery aTB patients (14–16), and those
where aTB lesions do not have access to the airways. As a
consequence, TB treatment is often started on a presumptive
diagnosis (17). Secondly, culture and PCR have shortcomings for
monitoring of the TB treatment response. MTB culture methods
have low sensitivity for unfavorable outcome and low positive
predictive value estimates (18). The GeneXpert PCR shows a lag
of positivity most likely due to detection of dead bacilli (19).
The current treatment duration is that of a “one-size-fits-all” 6-
months drug regimen without modifications based on treatment
response monitoring. Past trials conducted by the MRC East
Africa, and the more recent fluoroquinolone phase 3 studies,
have demonstrated that more than 80% of TB patients will
achieve cure after only 4 months of treatment (20–23). However
to introduce a 4-months treatment as a blanket approach, it
will be essential to discriminate between aTB patients who
achieve cure already after 4 months and those in need of longer
treatment. Sequential sputum bacterial load measurements by
culture have been tested in this regard, but have insufficient
sensitivity for detection of unfavorable treatment outcome on
an individual basis (19, 24). Together, these shortcomings in
mycobacteriological detection methods can impede accurate
diagnosis of aTB, meaningful TB treatment monitoring and
safe individualized treatment (21–23). The novel TAM-TB assay
approach could potentially improve TB diagnosis and treatment
monitoring; and hence help to overcome some of the challenges
affecting diagnosis solely based on the direct detection of MTB
bacilli in sputum. A prerequisite, herefore is a more detailed
understanding of the relationship between TAM-TB assay results,
the MTB infection status, and mycobacterial treatment response.
Here, we have therefore studied activation (CD38, HLA-
DR, and Ki67) and maturation (CD27) marker profiles on
IFNγ+ MTB-specific CD4T cells in subjects with LTBI, and in
aTB patients (25) before and after TB treatment initiation in
comparison to the mycobacteriological treatment response. The
patients were tightly monitored using MGIT culture on a weekly
basis until week 12 and on 4 additional time points until the end
of treatment at week 26 and showed no relapse during a 6months
follow-up after the end of treatment.
MATERIALS AND METHODS
Study Populations, Study Samples, and
Ethics Statements
HIVneg adult patients with culture confirmed aTB were enrolled
at two clinical sites in Tanzania (NIMR-MMRC, Mbeya, and
KCRI, Moshi) within the Panacea-TB MAMS treatment study
(Table 1, Figure 1; clinicaltrials.gov identifier NCT01785186)
(26). Four experimental treatments or the standard TB treatment
were given for 12 weeks, followed by 8 weeks of standard
treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol)
and by standard dose rifampicin and isoniazid to complete
TABLE 1 | Demography of study subjects.
PanACEA HISIS
Gender (Male/Female) 30/9 0/16
Median Age (Range) 34.4 (19.2–65.4) 32 (17.9–38)
Median BMI (Range) 19.2 (15.2–41.6) not determined
HIV status (+/–) 0/39 0/16
AFB sputum smear positivity grade (1/2/3) 3/10/26 Not applicable
Median Days to Positivity Baseline (Range) 3.5 (1–7.5) Not applicable
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FIGURE 1 | Diagram of study subjects, time points and TAM-TB analyses. Peripheral blood mononuclear cell samples from aTB patients (n = 39) were collected at
baseline, at week 9, 12, and 26 after TB treatment initiation and subjected to TAM-TB assay analyses. The numbers of missing samples and those excluded due to
none responsiveness to the positive control antigen SEB (“poor quality”) are indicated for each time point. PBMC samples (n = 16) from HIV- IGRA+ subjects were
collected during the HISIS cohort study.
26 weeks of treatment. All study participants received further
follow-up for 6 months after end of treatment by telephonic
interviews and site visits. Of the patients included in this sub-
study, 25 were in either one of the experimental treatment arms,
whereas 14 subjects received the standard treatment. None of the
patients relapsed during this 6-months follow-up. The protocol
was approved by independent ethics committees of the sponsor,
the trial sites, and the regulatory authorities of Tanzania and
South Africa. Additional samples from HIVneg IGRA+ healthy
female bar workers from the HISIS study (27) were included
as LTBI controls (n = 16). The HISIS study was conducted
at the NIMR-MMRC in compliance with national guidelines
and institutional policies, and informed consent was obtained
in accordance with the Declaration of Helsinki. The study was
approved by the local ethic board at Mbeya (FWA no. 00002469)
and the National Ethic Board at the National Institute forMedical
Research (FWA no. 00002632).
TAM-TB Assay
Cryopreserved Peripheral Blood Mononuclear Cell (PBMC)
samples from aTB patients (n = 39, Figure 1) from baseline,
9, 12, and 26 weeks were analyzed using the TAM-TB assay
approach. PBMC samples from subjects with LTBI (n = 16)
were included as additional controls. PBMCs were stimulated
overnight at 37◦C and 5% CO2 with Purified Protein Derivative
(PPD, 10µg/ml, Serum Staten Institute), SEB (0.6µg/ml, Sigma-
Aldrich) as a positive control, or no added peptide as negative
control in the presence of Brefeldin A (BFA, final concentration
5µg/ml, Sigma) and the costimulatory antibodies anti-CD49d
(L25, BD) and anti-CD28 (L293, BD). Cells were stained with
anti-CD38 BV785 (clone HIT2, Biolegend), anti-CD4 APC
(clone 13B8.2, Beckmann Coulter), anti-CD27 ECD (clone
1A4CD27, Beckmann Coulter), and anti-HLA-DR APC-H7
(clone G46-6, Beckmann Dickinson), followed by fixation and
permeabilization using FoxP3 Perm/Fix buffer and diluent
(eBioscience), and then stained intracellularly using anti-IFNγ
FITC (clone B27, BD Pharmingen), anti-Ki67 BV421 (clone
B56, BD Pharmingen), and anti-CD3 APC-A700 (clone UCHT1,
Beckmann Coulter). Cells were acquired on a CytoFlex Flow
cytometer (Beckman Coulter). Data analysis was performed
using FlowJo_V10. MTB-specific CD4T cell responses were
defined by a frequency of ≥0.03% of IFNγ+ CD4T cells after
PPD stimulation and by ≥2-fold increase over the negative
control. Furthermore, a cell count of greater than 25 IFNγ+
CD4T cell events had to be recorded. Samples with no response
to the positive control antigen Staphylococcal enterotoxin B
(SEB) were excluded from the analyses (n= 17). Pestle and Spice
software (28)were used to analyze combinatorial expresssion of
the four phenotypic markers on IFNγ+ MTB-specific CD4T
cells.
Bacteriological Assessments
Patients submitted sputum during weekly visits until week 12,
and at weeks 14, 17, 22, and 26. Sputum was decontaminated
with NaCl-OH, and cultured in liquid media; the mycobacterial
growth indicator tube (Bactec MGIT960), and on Löwenstein-
Jensen (LJ) solid medium (22). The primary study endpoint was
time from treatment initiation to the first of two consecutive
negative weekly sputum cultures without an intervening positive
or contaminated culture in liquid media.
Statistical Analysis
The Statistical analysis was performed using GraphPad prism
software version 6. The tests used are indicated in the Figure
Legends.
RESULTS
T Cell Activation Marker Expression
Profiles on MTB-Specific CD4T Cells
Differentiate Between aTB and LTBI
At time of diagnosis, all aTB patients had detectable MTB-
specific CD4T cell responses upon PPD re-stimulation (median:
0.22%, range 0.03–4.3%). None-stimulated controls showed no or
very little background in IFNγ+ T cells (median: 0.008%, range
0.0–0.066%). SEB stimulated controls showed high frequencies
of IFNg+ CD4T cells (median: 1.92%, range: 0.6–9.3%). High
frequencies of MTB-specific CD4T cells expressed the activation
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FIGURE 2 | Representative dot plots for phenotypic characterization of MTB-specific CD4T cells. Shown are dot plots for active TB (A), 12 weeks into TB treatment
(B) and Latent TB Infection (C). Dot plots are gated on CD4T cells showing IFNγ (x-axis) and activation (CD38, HLA-DR, and Ki67) and maturation (CD27) marker
staining (y-axis) without stimulation (upper panel) and after PPD stimulation (lower panel). IFNγ+ MTB-specific CD4T cells are indicated (red box). The cut-off for the
expression of each phenotypic marker is indicated as a black line.
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markers CD38 (median: 71%, Figure 3, representative dot plots
in Figure 2), HLA-DR (median: 49.3%) and Ki67 (median:
17.5%) with a predominance of CD27low cells (median: 91.3%),
upon PPD stimulation. TAM expression on MTB-specific CD4T
cells differed significantly and showed no overlap for the
frequencies of CD38pos and Ki67pos cells between aTB and LTBI
(both p < 0.0001). Frequencies of CD27high and HLA-DRpos
cells also differed (both p < 0.0001), but showed greater overlaps
between aTB and LTBI. Receiver Operating Characteristic (ROC)
curve analysis between aTB and LTBI (Supplementary Figure 1)
confirmed that the frequency of CD38pos and Ki67pos MTB-
specific CD4T cells differentiated best between aTB and LTBI
[Area under the Curve (AUC) = 1] with a defined cut-off of
31.55% for CD38 and 3.7% for Ki67 (Supplementary Figure 1).
T Cell Activation Marker Expression
Profiles On MTB-Specific CD4T Cells
Change Rapidly Upon TB Treatment
Initiation
Frequencies of activated MTB-specific CD4T cells declined
dramatically from pre-treatment to W9 post-treatment
(p < 0.0001, Figure 3), while CD27high cell frequencies remained
largely unchanged (p = 0.8). These treatment-induced changes
varied substantially between individuals and were exclusively
observed in the MTB-specific T cell compartment, but not in
the non-specific CD4T cells (Figures 4A–D, Ki67 not shown).
The numeric data for the underlying Figure 4 is provided in
Supplementary Table 1. Consequently the changes in CD38
and HLA-DR expression until week 9 differed significantly
between MTB-specific and total CD4T cells (p < 0.0001 for
both markers, Figures 4E,F). Only comparatively moderate
changes were observed between W9 and W26 for CD38pos and
HLA-DRpos cell frequencies. The median frequency of Ki67pos
cells declined further to 1.5% (p = 0.01) between W12 and
26, whereas the median frequency of CD27low cells remained
unchanged between before and at the end of treatment (median:
91%, Figures 3B,D). Using SPICE analyses (28) combinatorial
changes of the 4 phenotypic markers on MTB-specific CD4T
cells were analyzed (Figure 5). The pie chart arcs show that
TB treatment induced substantial reductions in MTB-specific
T cell frequencies co-expressing the activation markers CD38,
HLA-DR, and Ki67 in different combinations as shown.
CD38 and CD27 Expression Phenotypes
Differentiate 3 MTB Infection States: Active
TB Disease, Treated TB, and Latent MTB
Infection
We next addressed the question whether and to what degree
the expression of activation and maturation markers on MTB-
specific CD4T cells correlate with one another and analyzed data
FIGURE 3 | Phenotypic profiles of MTB-specific CD4T cells in subjects with aTB, after TB treatment initiation and during LTBI. The frequency of MTB-specific CD4T
cells expressing the activation markers CD38 (A), Ki67 (B), HLA-DR (C), and the maturation marker CD27 (D) is shown on the y-axis for pulmonary TB patients
(purple circles) at baseline, 9, 12, and 26 weeks (x-axis) after TB treatment initiation. Subjects with latent MTB infection were included as controls (green diamonds).
MTB-specific CD4T cells were characterized after PPD stimulation. Statistical analyses were performed using the Mann-Whitney test. Median values, interquartile
range and p-values below 0.05 are indicated.
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FIGURE 4 | Detection of dynamic changes in CD38 and HLA-DR expression upon TB treatment initiation on MTB-specific, but not total CD4T cells. The frequency of
T cells expressing the activation markers CD38 and HLA-DR (y-axis) are shown for MTB-specific CD4T cells (A,B) and for total CD4T cells (C,D) before and at 9 and
12 weeks after treatment for each subject. MTB-specific CD4T cells were characterized after PPD stimulation. The slopes of the activation marker expression on
MTB-specific and on total CD4T cells were compared for CD38 (E) and HLA-DR (F) between baseline and week 9 (n = 29). Statistical analyses for paired data were
performed using the Wilcoxon-signed rank paired test. None-paired data analyzed using the Mann-Whitney test. P-values below 0.05 are indicated.
from aTB patients before and after TB treatment (n= 109 subject
visits, Figure 6). The frequency of all the activation marker
positive cells correlated with each other (all p < 0.0005). The
strength of correlation varied; CD38 and HLA-DR expression
correlated most strongly (Spm Rho = 0.76). The correlation of
Ki67 with either CD38 orHLA-DRwas comparatively weak (Spm
Rho = 0.35 and 0.33, respectively). A weak inverse correlation
was detected for the frequencies of CD27high cells with HLA-
DRpos (data not shown, both p < 0.05). In contrast, frequencies
of CD27high MTB-specific CD4T cells did not correlate with
the frequencies of CD38pos and Ki67pos cells (Figure 6D and
data not shown, p = 0.79 and p = 0.4, respectively).
Hence, simultaneous assessment of CD38 and CD27 holds most
information on TB disease and treatment status. Indeed, by
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FIGURE 5 | SPICE analyses for in-depth phenotypic profiling of MTB-specific CD4T cells. Shown are SPICE pie charts visualizing the mean frequency for each of the
16 possible phenotypic profiles of MTB-specific CD4T cells. The arcs indicate the proportion of cells that express CD27 (red), CD38 (green), HLA-DR (light blue)
and/or Ki67 (dark blue). The time point or LTBI infection status is indicated below each pie chart.
assessing only these two markers, the phenotypic characteristics
of MTB-specific CD4T cells at week 26 still differed from
LTBI with median frequencies of 28.8 and 12.1% for CD27high
(p = 0.0003) and CD38pos cells (p = 0.008), respectively. Hence,
phenotypic profiles differed significantly between aTB (profile:
CD38pos, CD27low), treated TB (CD38neg/pos, CD27low), and
LTBI (CD38neg, CD27high).
Treatment Induced Reductions in TAM
Expression Profiles on MTB-Specific CD4T
Cells Reflect Declining Bacterial Burden in
Sputum
Using the cut-off of < 31.55% CD38pos MTB-specific CD4T
cells to define LTBI, 37.5% (12 of 32) and 51.4% (18 of
35) of aTB patients had a TAM-TB profile consistent with
“LTBI” at W9 and W12 post-treatment, respectively. To address
whether such a phenotypic profile—determined at a single
post-treatment time point—indicates in vivo mycobacterial
clearance, we compared the time to last culture-positive result
from these patients with this “cured TAM-TB assay profile”
to those without such a TAM-TB profile. The two groups
did not differ (p = 0.58, data not shown) and those with a
“cured signature” still included 5 and 4 subjects, who were
still culture positive at or after W9 and W12, respectively.
Similar results were obtained using a more stringent cut off of
<19.7% CD38pos MTB-specific CD4T cells, which defined the
lower quartile of CD38pos cells at W12 (p = 0.26). Hence, a
“cured” TAM-TB signature measured at a single post-treatment
time point was not suggestive for clearance of viable bacteria
in sputum nor did it differentiate rapid from slow treatment
responders.
We next addressed whether changes in the frequencies of
T cell activation marker positive MTB-specific CD4T cells
between baseline and W9; and between baseline and W12
were linked to treatment-induced bacterial clearance using
the primary PanACEA study endpoint—time to stable culture
negativity. 32 of 39 subjects had TAM-TB results at baseline
and at W12 and/or W9 and thus the slope for the change in
expression of the individual TAMs after treatment initiation
could be determined. 15 of these 32 subjects also had an
accurate endpoint determination of ≤ 4 weeks between the
last positive and stable culture conversion (Figure 7). In the
other 17 subjects, determination of the accurate time to
culture conversion was compromised due to increasing rates
of culture contamination as treatment progressed—a common
phenomenon (29). These either did not reach stable culture
conversion or had large gaps between the last positive and
stable culture conversion and hence were excluded from analyses.
Taking into consideration baseline and W12 results, the slope
of decline in expression of CD38 (p = 0.0045, Rho = 0.7)
and HLA-DR (p = 0.02, Rho = 0.61) on MTB-specific CD4T
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FIGURE 6 | Correlation analysis of activation and maturation marker expression on MTB-specific CD4T cells. The proportion of IFNγ+ MTB-specific CD4T cells
expressing activation and maturation markers after stimulation were plotted for CD38 and Ki67 (A), CD38 and HLA-DR (B), Ki67 and HLA-DR (C), CD38 and CD27
(D) on the y- and x-axis, respectively for samples from subjects with aTB from before and after treatment initiation (n = 109). The Spearman’s rank test was used for
statistical analysis.
cells correlated with the time to stable culture conversion
(Figures 8A,B). Likewise, similar correlations were detected
when considering measurements at baseline and week 9 (n =
13 subjects, CD38: p = 0.015, Rho = 0.67; HLA-DR: p = 0.007,
Rho = 0.72, Figures 8C,D). No such correlations were detected
for CD38 and HLA-DR expression on total CD4T cells (data not
shown).
DISCUSSION
Substantial reductions in the expression of activation markers
on MTB-specific CD4T cells were observed at W9 into TB
treatment for most patients. In contrast, expression of these
markers on total CD4T cells remained comparable to pre-
treatment values, showing that TB treatment-induced changes
in T cell activation status are specific to the MTB-specific T
cell compartment. Individual patients varied substantially in
the early reduction in MTB-specific CD4T cell activation until
week 9 and week 12; and for both of these time intervals,
the degree of change in activation correlated well with the
mycobacterial response. Our data therefore provide evidence
that early changes in TAM expression profiles on MTB-specific
CD4T cells reflect clearance of viable mycobacteria in vivo. These
TAM-TB profiles may therefore serve as a surrogate marker
for treatment efficacy, as originally proposed by Adekambi
et al. (5) and now further substantiated in more aTB patients
with more precisely determined time to culture conversion.
This immunological approach therefore bypasses the issues
associated with the collection of sputum specimen (e g., in
young children, after TB treatment initiation) and increased
culture contamination rates as treatment progresses (29); which
renders treatment monitoring by serial cultures difficult and
often imprecise on a per person level, as was observed in our
patient subset. It is noteworthy, that all tested TB patients
responded to the MTB antigen PPD, therefore enabling the
determination of the activation status on MTB-specific CD4T
cells.
Shortening treatment is a major objective of TB drug
development and has been tested in 4 recent studies (20–23);
the majority (at least 80%) of patients treated in these trials
for only 4 months had been cured without relapse within the
defined follow up of 18 months; but nevertheless the trials
were declared unsuccessful due to high relapse rates in the
4 months regimens. While speculative at this point, a TAM-
TB assay approach based treatment-monitoring algorithm could
therefore potentially help to personalize TB treatment duration
by discrimination of patients who respond well to TB treatment
marked by a substantial reduction in MTB-specific CD4T cell
activation—and those who do not.
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FIGURE 7 | Sequential MGIT culture results. Sequential MGIT culture results from 17 study visits from week 0 to week 26 (x-axis) are shown for each subject with a
TAM-TB assay result from baseline and/or at week 9 and/or week12 (n = 32). The upper and lower line graphs indicate culture results from subjects with ≤ 4 (n = 15)
and ≥4 weeks (n = 17) between the last positive and stable culture conversion, respectively. Red dots indicate a MTB positive culture result, green dots a negative
culture result, and gray dots indicate a contaminated sample. Dark green squares indicate stable culture conversion defined as the first of two consecutive culture
negative results. Dark red square*: last culture positive sample before 2 consecutive culture negative samples.
The dynamic changes in expression of T cell activation
markers observed upon treatment initiation contrasted with
the minor changes observed for the maturation marker
CD27. We assessed, which combination of markers are most
informative on treatment and disease/infection status. Consistent
with previous results (5), expression of CD38 differentiated
best between aTB and LTBI. The three activation markers
correlated with one another and thus the determination of
one activation marker—CD38—might suffice to differentiate
active TB from LTBI and to monitor the treatment response.
No correlation was detected between expression of CD38 and
CD27 and the latter best differentiated treated TB at W26
from LTBI. Hence, simultaneous assessment of CD38 and
CD27 expression on MTB-specific CD4T cells, can help to
differentiate between three MTB infection/disease states; (1)
aTB—defined by high expression of activation markers, but
low CD27 expression; (2) LTBI—defined by low expression
of activation markers and high expression of CD27 and
(3) treated TB—defined by low expression of activation
markers and continuously low CD27 expression. Our data
therefore support the concept that phenotypic characteristics
of pathogen-specific T cells may not only differentiate between
active TB and LTBI, but may also detect past episodes of
pathogen activity, which were resolved through treatment or
naturally.
Previous reports on CD27 expression on MTB-specific CD4T
cells also showed no substantial increase by 26 weeks of treatment
(6). However, at 12 months after the end of TB treatment it
appears to revert to levels characteristic for LTBI (8). It could
be that residual TB disease activity at the end of TB treatment
and during LTBI, might contribute to such a CD27low profile,
as suggested by a recent positron emission tomography (PET-
CT) study. This study showed persistent, active lesion activity
in the majority of cured TB patients even until 6 months
after TB treatment (30). A large range of bacterial loads and
metabolic activity in MTB lesions (31–33) has also been observed
in non-human primates with LTBI consistent with a broad
spectrum between LTBI, treated and active disease (34, 35). We
had previously reported on a HIV seroconverter where CD27
downregulation on MTB-specific T cells preceded active TB
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FIGURE 8 | Changes in TAM expression profiles on MTB-specific CD4T cells upon treatment initiation reflect declining bacterial burden in sputum. A correlation
analysis between time to stable culture conversion and the slope of CD38 and HLA-DR marker expression dynamics on IFNγ+ MTB-specific CD4T cells is shown for
the time interval from baseline to week 12 (A,B, n = 15), and from baseline to week 9 (C,D, n = 13), respectively, for subjects with accurately defined time point of
less than 5 weeks between the last positive MGIT culture result and stable culture conversion. The Spearman’s rank test was used for statistical analysis.
diagnosis by 6–9 months (2). It would therefore be of great
interest to better define the range of expression of phenotypic
markers on MTB-specific T cells and other host response
markers (36–38) in relation to the presence and dynamics
of TB lesions in vivo in subjects with LTBI and in patients
after treatment initiation (30) with systematic follow up on
active TB disease progression, and treatment failure and relapse,
respectively.
It is known that males account to 65% of aTB patients
globally (39). Our LTBI control group consisted only of females,
which raised the concern whether gendermight have confounded
our results. To address this question, males (or females) were
excluded in a sub-group analysis (Supplementary Figure 2);
there was no overlap of CD38 and Ki67 in subjects with
LTBI and aTB, when considering only females (p < 0.0001).
Further, no gender-associated difference in the TAM-TB profile
at baseline was detected, whereas significant reductions in T cell
activation marker expression—but not for CD27 expression—
were induced by TB treatment regardless of gender. Hence
there was no evidence that gender alone influenced the TAM-
TB profile of MTB-specific CD4T cells in our study. It
is however noteworthy that males had significantly higher
frequencies of proliferating (Ki67+) MTB-specific CD4T cells
and a trend for increased expression of CD38 at 12 weeks
post treatment initiation (p = 0.09) compared to females
(data not shown). The latter finding is “consistent” with
another finding of the Panacea-TB MAMS treatment study;
females cleared mycobacteria significantly faster upon treatment
initiation as compared to males (unpublished results). Hence,
gender-associated differences in activation marker profiles of
MTB-specific CD4T cells at 12 weeks after treatment initiation
probably reflect gender-related differences in the rate of
mycobacterial clearance.
Limitations in this study were the lack of available X-ray
scores as well as disease severity assessment. We were also
not able to study the effect of HIV infection on TAM-TB
assay profiles during treatment monitoring, because our cohort
recruited exclusively HIV negative patients. HIV infection is
associated with increased levels of systemic T cell activation
(40, 41). Another study investigated the effect of HIV on MTB-
specific CD4T cell activation, andmaturation, showing only little
influence (7). Larger studies in well-characterized cohorts need
to clarify the influence of these parameters on TAM-TB assay
results and their changes upon treatment initiation. While the
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need for flow cytometry and basic cell culture methods may
limit the use of this approach in resource poor settings, our
data show that more complex flow cytometry is in principle not
needed. We and others have previously shown that by using
whole blood this assay can be simplified substantially (2, 42).
Other methods assessing the MTB-specific cytokine secretion
upon whole blood stimulations may also allow specific diagnoses
of active TB (43), whereas monitoring the TB treatment response
using the latter approach so far appears less promising (44). The
measurement of soluble biomarkers in the blood without prior
stimulation also may hold valuable information on TB disease
and treatment status (45). The diagnostic value of these needs
further investigation.
In conclusion, our data on using phenotypic profiles of MTB-
specific CD4T cells as a surrogate marker for treatment efficiency
warrant further research and methodological simplification to
define its usefulness in standard clinical sttings and during TB
drug trials.
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There remains an urgent need for a prophylactic HIV vaccine. We compared combined 
MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected 
Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 
100% individuals after boosting with gp140 and that combined vaccines would not 
compromise safety and might augment immunogenicity. Forty volunteers were primed 
three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 
and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl 
lipid adjuvant—aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were 
randomised to receive them in combination at the same visit at 16 and 20 weeks (accel-
erated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks 
(standard). All vaccinations were intramuscular. Primary outcomes included ≥grade 
3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes 
included neutralization, binding antibody specificity and T-cell responses. Two partici-
pants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of 
vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 
100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the 
response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization 
of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% 
responders, p =  0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 
and 82% responding in the accelerated and standard groups, respectively. Vaccine-
induced IgG responses targeted multiple regions within gp120 with the V3 region most 
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In an era of antiretroviral medication for the treatment and pre-
vention of HIV, concerns around access, toxicity, and escalating 
cost suggest that a vaccine for HIV is still likely to be the most 
effective and sustainable way of reducing new infections (1, 2). 
Of the five HIV efficacy vaccine trials to date, there has only been 
only one to demonstrate significant, if modest efficacy; the RV144 
“Thai” trial (3–8). This study with 16,402 subjects randomized 
to four immunizations with ALVAC given twice and then twice 
more with AIDSVAX B/E adjuvanted with ALUM, reported 31.2% 
protection (95% CI 1–51) against acquisition, without impacting 
HIV viral load or CD4+ T cell count (8). Subsequent immuno-
logical analyzes reported an inverse correlation between the levels 
of circulating polyclonal non-neutralizing antibodies and risk of 
infection, which has been associated with Fc receptor-mediated 
antibody effector functions (9–15). The results stimulated interest 
in prime-boost pox and protein combination vaccine approaches 
and the role of non-neutralizing antibodies.
Heterologous prime boost regimens employing DNA, viral 
vectors, and/or recombinant proteins have generated robust cel-
lular and humoral responses maximizing breadth and potency 
while limiting the attenuating effects of vector specific immunity 
(16–20). DNA vaccines have been shown to prime cellular and 
humoral immune responses, upon boosting with recombinant 
vectors (21). The EuroVacc trials demonstrated that DNA prime, 
NYVAC boost increased the frequency, magnitude, and breadth 
of HIV-specific T-cell ELISpot responses (22, 23) and that three 
DNA priming immunizations were more immunogenic than 
two (24). A recent clinical trial comparing different prime boost 
regimens showed no benefit of DNA priming for Env-specific 
antibody responses but evidence of an improvement in T-cell 
responses, although overall immunogenicity was lower than seen 
previously in response to the same DNA and MVA vaccines (25).
In this study, the UK HIV Vaccine Consortium built upon 
these prior data showing enhanced immunogenicity of DNA 
prime, pox vector boost, and the protection seen in RV144 by 
protein boosting, to produce homologous DNA, MVA, and 
gp140 immunogens. We have made DNA plasmids and an MVA 
expressing matched HIV-1 subtype C (CN54)-derived inserts, 
and adjuvanted trimeric glycoprotein with a view for use in 
Sub-Saharan Africa. We believe this strategy is ideally suited to 
inducing Env-dominant CD4+ T-cell responses, favoring the 
development of high titer Env-specific antibody responses. The 
same trimeric recombinant CN54gp140 protein has already been 
administered to 469 individuals in a variety of trial settings (with 
and without DNA priming, or adjuvant and via different routes), 
showing excellent safety and induction of vaccine specific anti-
bodies (26–28). When given systemically with glucopyranosyl 
lipid adjuvant—aqueous formulation (GLA-AF) after priming 
with heterologous DNA and MVA, high titer systemic binding 
antibodies were seen to the protein (28).
Prompted by the results of the RV144 trial, but with long-term 
feasibility in mind, we have explicitly assessed the impact of 
combining pox (MVA-C) and GLA-AF adjuvanted CN54gp140 
protein after priming with DNA. We compared the safety and 
immunogenicity of two regimens using identical vaccines; given 
sequentially in one regimen (standard) and with the pox and 
protein combined in the other (accelerated). We shortened the 
regimens relative to our previous studies and RV144 by reducing 
the intervals between vaccinations, with 4 weeks between each 
of three DNA immunizations, 8 weeks between prime and first 
boost, and 4 weeks between subsequent boosts. We administered 
vaccinations intramuscularly (IM) for logistical ease and with a 
view to eventual roll out in resource limited settings.
The DNA and MVA-C were produced by UK HVC and based 
closely on those used previously (EV02 Eudract 2004-001802-28 
and EV03 Eudract 2006-006141-13), with matched CN54/ZM96 
subtype C-derived gag pol nef and env inserts. We anticipated 
Env-dominated CD4+ T-cell responses and modest Env-specific 
antibody responses after DNA and MVA, with the development 
of high titer binding and neutralizing antibody responses after 
boosting with adjuvanted CN54gp140 protein (29–31). Based 
on our previous studies, we expected that the immunogens 
would prove more potent B-cell immunogens than the ALVAC/
AIDSVAX/ALUM used in RV144 and that the combined MVA/
CN54p140/GLA might augment immunogenicity, offering the 
potential for a short regimen.
MaTerials anD MeThODs
study Design and conduct
This was a Phase I randomized open-label trial conducted at 
two UK centers: Imperial College London and Surrey Clinical 
Research Centre. Participants were recruited through advertising, 
immunodominant and no differences between groups detected. Combining MVA and 
gp140 vaccines did not result in increased adverse events and did not significantly 
impact upon the titer of Env-specific binding antibodies, which were seen in 100% indi-
viduals. The approach did however affect other immune responses; neutralizing antibody 
responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were 
combined and while T-cell responses were seen in >80% individuals in both groups and 
similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when 
the vaccines were combined, suggesting attenuation of immunogenicity and cautioning 
against this accelerated regimen.
Keywords: hiV vaccine, phase i trial, Dna, MVa, envelope protein
FigUre 1 | Trial flow.
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social media, and a dedicated website. The study documents were 
reviewed and approved by the NRES London—West London and 
GTAC Ethics Committee (13/LO/0115), and the UK Medicines 
and Healthcare products Regulatory Agency, and all participants 
gave fully informed written consent according to the Declaration 
of Helsinki before any study procedures were conducted. The 
trial was registered with the European Union Drug Regulating 
Authorities for Clinical Trials (EUDRACT TC 2012-003277-26) 
and Clinical Trials.gov (NCT01922284) and with the UK Clinical 
Trials Research Network (UKRN-14173). Laboratory personnel 
were blind to the allocation. Participants were block randomized 
centrally using a computer generated algorithm with a back-up 
manual procedure, and the randomization list was stratified by 
center and gender.
The primary objective was to compare the safety and immu-
nogenicity of two vaccination regimens, one of which was 
shortened by 8  weeks (Figure  1) in healthy HIV-uninfected 
male and female volunteers aged 18–45 years at low risk of HIV 
infection. The primary outcomes were (i) a severe (grade  3) 
or worse local or systemic clinical or laboratory adverse event 
or an event that led to a clinical decision to discontinue vac-
cinations and (ii) the magnitude of the CN54gp140-specific 
IgG antibody response in serum 4  weeks after the final 
immunization. Secondary outcomes of interest included IFNγ 
T-cell ELISpot, intracellular cytokine, neutralizing antibody, 
CN54gp140-specific serum IgA, mucosal IgG, and IgA anti-
body responses.
safety evaluations
Local and systemic events recognized to be associated with 
licensed vaccines were solicited systematically at clinical cent-
ers prior to, 10 min and 1 h after each vaccination, and then 
7 days later, and by diary card. Clinical and laboratory events 
were collected via an open question at each visit and through 
routine hematology and chemical pathology performed at 
screening, 1 week after each vaccination and at week 40 in both 
groups.
Table 1 | schedule of doses, formulation, and routes of immunization.
group route of immunization; dose of vaccine
Weeks 0, 4, 8 Weeks 16, 20 Weeks 24, 28
1 (n = 20) 4 mg DNA (CN54) in 
1 ml (right arm)
1 × 108 TCID50 






in 0.4 ml (right arm)
Nothing
4 mg DNA (ZM96) in 
1 ml (left arm)
Intramuscular (IM) IM
2 (n = 20) 4 mg DNA (CN54) in 
1 ml (right arm)
1 × 108 TCID50 MVA-C 
in 0.5 ml (left arm)
(100 µg 
CN54gp140 + 5 µg 
GLA-AF) in 0.4 ml 
(right arm)
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immunological specimens
Blood was taken for immunological assessments at weeks 0, 4, 8, 
16, 20, and 24 and 40 for all participants and at weeks 28 and 32 
for those in the standard group. Mucosal samples were collected 
at weeks 0 and 24 for the accelerated and at weeks 0 and 32 for the 
standard group. Peripheral blood mononuclear cells (PBMCs) 
were isolated using density gradient separation, frozen in a mix-
ture of fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) 
and DMSO (9:1 ratio) using a Kryo 560-16 rate controlled freezer 
(Planer, Sunbury-On-Thames, UK). PBMCs were shipped and 
stored in vapor phase liquid nitrogen as previously (32). Genital 
tract secretions from women were collected using the Instead 
Softcup™ (Evofem Inc.) and urethral swabs (Hunt Biologics, 
UK) from male volunteers and rectal Floq™ swabs were taken 
when possible from males and females, primarily to assess the 
feasibility of the sampling method. Vaginal samples were col-
lected, processed, and analyzed as described previously (33). 
Urethral swabs were collected from male participants in clinic by 
inserting the swab and allowing it to absorb mucosal secretions 
for 2 min. Rectal Floq™ swabs were inserted into the anus and 
rotated to collect secretions. Rectal and urethral swabs were either 
snap frozen on receipt or processed directly. Processing involved 
addition of 300 µl of extraction buffer [250 mM NaCl, 1× protease 
inhibitor cocktail set 1 (Calbiochem) in phosphate buffered saline 
(1× DPBS)] to the swabs, vortexing for 1 min and placing on ice 
to 15 min. Rectal and urethral swabs were then placed in the top 
chamber of a spin X tube, centrifuged at max speed (10,000 g) for 
2 min and the eluates either analyzed immediately or aliquoted 
and frozen at −80°C until analysis.
Vaccines and schedule
The recombinant clade C HIV-1 envelope gp140 protein 
(CN54gp140) is a naturally cleavage resistant envelope clone of 
97CN54 (34). The protein was manufactured to GMP specifica-
tion (33) (Polymun Scientific Austria) generating a product which 
was >80% trimeric protein with a projected mass of 420 kD and 
a defined glycan (35). A total of 100 µg CN54gp140 was mixed 
with 5 μg GLA-AF (IDRI, Seattle, WA, USA) and administered 
in a volume of 0.4 ml as below. There were two DNA plasmids; 
one encoded (CN54) env and the other a (ZM96) gag-pol-nef 
fusion protein. Both open-reading frames were RNA and codon 
optimized (GeneArt AG, Regensburg, Germany). Both plasmids 
utilized a chimeric CMV enhancer/promoter with a human 
T-cell leukemia type 1 regulatory element to drive expression 
(36). The MVA-C (Mariano Esteban CSIC, Spain) expressed the 
CN54gp120 Env and Gag-Pol-Nef polyprotein from two back-to-
back synthetic early/late transcriptional promoters (37, 38). All 
vaccinations were given IM into the deltoid muscles of the upper 
arms. 4 mg of each DNA plasmid was given to all participants at 
weeks 0, 4, and 8 in a volume of 1.0 ml (8.0 mg in total) with the 
same plasmid given into the same arm on each occasion (CN54 
plasmid into right arm and ZM96 into left arm). In the “standard” 
group, 108  TCID50 MVA-C was given at weeks 16 and 20 in a 
volume of 1.0  ml (into left arm) and then 100  µg CN54gp140 
mixed with 5 µg GLA-AF at weeks 24 and 28 in a volume of 0.4 ml 
(into right arm). In the “accelerated” group, 108  TCID50 MVA-C 
in 1.0 ml was given at the same time as 100 µg CN54gp140 mixed 
with 5 µg GLA-AF at weeks 16 and 20 in 0.4 ml IM as above (with 




Serum and mucosal binding antibodies against recombinant 
CN54gp140 were measured using a standardized ELISA with 
minor modifications. 96-well ELISA plates were coated with 
50 µl per well of capture antigen CN54gp140 (1 µg/ml) (Polymun, 
Austria). Human standards (IgG or IgA) were captured by coat-
ing wells with a combination of α-Human κ and α-Human λ 
(1:1 ratio) capture antibodies. After incubation at 37°C for 1 h, 
plates were washed with PBST then blocked for 1  h at 37°C 
with 200 µl/well of assay buffer (PBS + 1% BSA) then washed, 
as above (26). Standards were prepared by adding the required 
concentration of either human IgG or IgA. Serum samples were 
screened at 1:100 dilution, Softcup cervical mucosal samples at 
1:10 dilution. Samples, standards, and controls (normal human 
sera) were added to triplicate wells. Detection antibodies were 
added following incubation and washing, either goat α-Human 
IgG-HRP or goat α-Human IgA-HRP detection antibodies. 
After incubation and washing, plates were developed by the 
addition of TMB substrate (KPL) followed by addition of 50 µl 
of Stop Solution (KPL). Absorbencies were read immediately 
at 450 nm using a VersaMax plate-reader (Molecular Devices). 
A response detected for both IgG and IgA was defined as OD 
A450  nm value >0.2; samples below this value were deemed 
negative or response not detected. Samples were further diluted 
following screening assays if positive with a series of dilutions 
in order to extrapolate a concentration expressed as microgram 
per milliliter of specific IgG or IgA using the ELISA software 
SoftMax Pro v 5.4. Serum samples that were positive by the 
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above method were also tested in a conventional endpoint titer 
assay as previously described (32).
Neutralizing Antibody Responses
Neutralizing antibody responses against a panel of Tier 1 
(MW965.26, MN.3, 00836-2.5, ZM197M-PB7) and Tier 2 
(Ce1176_A3, Ce703010217_B6, HIV-2510-2) pseudo viruses 
were measured using TZM-bl cells in the lab of David Montefiori 
as described previously (27, 39). Briefly, pseudoviruses (TZM-bl 
assay) were incubated with serial dilutions of sera and added to 
their respective target cells. Luciferase expression was measured 
after 2 days (TZM-bl), and IC50s were determined as the serum 
concentration that reduced the background-subtracted relative 
light units by 50% compared to virus-only control wells.
cellular assays
IFNγ ELISpot
Cellular immunogenicity was assessed by standardized IFNγ 
ELISpot assay using frozen PBMCs as previously described (32, 
39). One day prior to assay setup, PBMCs were thawed in and rested 
overnight in RPMI medium containing 20% heat-inactivated 
fetal calf serum (HIFCS), glutamine, penicillin, and streptomycin 
(R20) (all supplied by Sigma, Poole, UK) at 37°C, 5% CO2. 96-well 
PVDF membrane (MSIPS4510 Millipore, UK) plates were coated 
with mouse anti-human IFNγ (10μg/ml; MabTech clone 1-D1K) 
in sterile PBS. On the day of assay setup, coated ELISpot plates 
were washed with sterile PBS and blocked with RPMI 10% HIFCS 
(R10) for at least 1 h. Synthetic peptides (15-mers overlapping by 
11aa; HPLC purified >90%, JPT Germany) covering the HIV-1 
gene inserts and CMV pp65 gene were dissolved and pooled in 
dimethyl sulfoxide (DMSO, Sigma), further diluted in PBS and 
R10 to achieve a final assay concentration of 1.5 µg/ml per peptide 
and 0.45% v/v DMSO. 100  µl volumes of HIV-1 peptide pools 
were added to ELISpot plate wells in quadruplicate. The CMV 
pp65 peptide pool and phytohemagglutinin (PHA, 10  µg/ml) 
were plated as positive controls in duplicate wells for each. For a 
negative control, quadruplicate wells containing a mock stimulus 
(0.45% v/v DMSO final concentration in R10) were used. Rested 
PBMCs were recovered and washed in R10 and viable cells counted 
using a Beckman Coulter Vi-Cell counter. A total of 200,000 viable 
PBMCs (in 50 µl) were added to all wells except for 1 well with 
R10 only (reagent control well). Plates were incubated at 37°C, 5% 
CO2 overnight (16–24 h). All subsequent steps were performed at 
room temperature. Plates were washed six times with PBS/0.05% 
v/v Tween 20 (Sigma) and the production of IFNγ by T-cells was 
assessed by addition of 1 μg/ml biotinylated mouse-anti-human 
IFNγ antibody (clone 7-B6-1, Mabtech, Sweden) for 2–4 h. Plates 
were washed as before and ABC peroxidase–avidin–biotin com-
plex (PK6100, Vector labs, UK) was added for 1 h, followed by 
three washes with PBS/Tween and three washes with PBS. Spots 
were developed with addition of filtered AEC/H2O2 substrate 
solution (Sigma) for 4 min. The reaction was stopped by wash-
ing plates under running tap water, plate underdrains removed, 
and plates allowed to dry overnight in the dark before spots in 
each well were counted using an automated AID ELISpot reader 
(AutoImmun Diagnostika, Germany).
A positive response was defined by the following criteria: 
(1) average number of background-subtracted spots in a single 
pool >specified cutoff of 38 SFC/106 PBMCs (40). The cutoffs 
were derived from assessing peptide pool responses in PBMCs 
from 178 HIV-1 seronegative individuals; (2) for each pool, 
if the number of replicates was 2 or ≥3, then the coefficient of 
variation (standard deviation/mean) between replicates had to be 
≤50% or ≤70%, respectively; (3) mean count had to be >4 times 
mean background; (4) mean background had to be ≤55 SFC/106 
PBMCs. Samples with mean background >55 SFC/106 PBMCs 
were considered failures, were repeated, and excluded from all 
analyses if failed a second time. The breadth of responses was 
described in terms of the number of individual peptide pools to 
which each individual responded.
Flow cytometry
Antigen-specific cytokine secretion was assessed using a vali-
dated seven-color polychromatic flow cytometry panel assessed 
at the IAVI human immunology lab in London. Previously 
frozen PBMCs were coincubated with peptide pools matched 
to the inserts at 1.5  µg/ml (as previously described), 1  µg/ml 
SEB (Sigma-Aldrich, St. Louis, MO, USA), or mock stimuli and 
Brefeldin A (Sigma-Aldrich, Poole Dorset, UK) for 6 h at 37°C. 
Cells were stained for viability with LIVE/DEAD Fixable Violet 
Dead Cell Stain Kit (Invitrogen, Eugene, OR, USA), fixed and then 
stained intracellularly using anti-CD4 PeCF594 (clone RPA-T4), 
anti-CD8 BV421 (RPA-T8), anti-CD3 APC-H7 (SK7), anti-IFNγ 
APC (B27), anti-IL2-PE (MQ1-17HI2), and anti-TNFα-FITC 
(Mab11) (all Becton Dickinson, San Jose, CA, USA). Cells were 
washed and acquired on the same day. At least 5,000 CD8 and 
CD4+ CD3+ viable, singlet lymphocyte events were acquired 
using BD Fortessa II instruments. Data were analyzed and pre-
sented using FlowJo (version 9.8 Treestar, Ashland, OR, USA). 
Samples were failed where fewer than 5,000 events in the prede-
fined populations were acquired or where mock IFNγ responses 
were above 0.2% of either parental population. Flow cytometric 
analysis was performed at baseline, and 16 and 24 weeks for group 
1, and additionally at 32 weeks for group 2.
Peptide array Mapping
The microarrays were processed according to the manufacturers 
instructions with minor modifications (www.jpt.com). Briefly, 
the slides were pre-incubated with T20 blocking buffer (Thermo 
Fisher) for 10 min. Plasma samples were then added at a dilu-
tion of 1:100 in T20 blocking buffer and incubated for 2  h at 
room temperature with gentle shaking before washing five times 
with 2.5  ml TBS-Tween (0.5% Tween). The secondary mouse 
anti-human-IgG Dylight649 (JPT) was then incubated at room 
temperature for 1 h at a dilution of 1:5,000 in T20 blocking buffer. 
After five washings with 2.5  ml TBS-Tween, and five washes 
with double distilled de-ionized water, the slides were left to dry 
under a laminar flow hood. Samples from all timepoints from one 
individual were processed simultaneously. Slides were scanned 
on a GenePix 4000A scanner and processed using GenepixPro 
6.0 software at 650 and 532 nm to generate a Tiff image file. The 
array lay out was then added using the .gal file JPT_2758_V04.gal 
provided by JPT. Accuracy of the array alignment was controlled 




Number 20 20 40
Age (SD) 31 (25–38) 32 (22–39) 32 (23–39)
Center
 Imperial College 10 (50%) 10 (50%) 20 (50%)
 Surrey 10 (50%) 10 (50%) 20 (50%)
Gender
 Female 10 (50%) 9 (45%) 19 (47.5%)
 Male 10 (50%) 11 (55%) 21 (52.5%)
Ethnicity
 Asian 2 (10%) 0 (0%) 2 (5%)
 Mixed 0 (0%) 2 (10%) 2 (5%)
 White 18 (90%) 18 (90%) 36 (90%)
Weight (kg) 73 (63–82) 72 (67–78) 72.8 (66–78)
Routine laboratory parameters
 Hemoglobin (g/dl) 14 (13–15) 14 (13–14) 14 (13–15)
 White cell count (109/l) 7 (5.3–8.2) 6.4 (5.8–8.0) 6.5 (5.6–8.2)
 Neutrophils (109/l) 4.1 (2.9–5.1) 3.6 (3.3–5.1) 3.8 (3.0–5.1)
 Platelets (109/l) 250 (236–288) 259 (225–289) 250 (219–288)
 Lymphocytes (109/l) 1.9 (1.6–2.3) 1.9 (1.6–2.3) 1.9 (1.5–2.3)
 ALT (U/l) 20 (19–25) 19 (14–27) 21 (16–27)
 AST (U/l) 21 (18–26) 23 (18–27) 23 (18–27)
 Bilirubin (μmol/l) 10 (9–14) 11 (7–15) 10 (7–14)
 Creatinine (μmol/l) 71 (58–78) 71 (59–84) 71 (60–80)
 Glucose (mmol/l) 4.7 (4.4–5.0) 4.6 (4.5–4.9) 4.6 (4.4–4.9)
DNA/ANA antibodies
 Positive 4a (20) 0 4
 Negative 16 (80) 20 36
Follow-up (weeks, range) 43 (40–46) 45 (30–50) 44 (30–50)
aPositive only at a dilution of 1:160 which was deemed eligible.
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and individual features were adjusted or excluded manually when 
needed. After this QA/QC step, .gpr files were generated and 
processed further into .dat files using R-program and the R-script 
“MakeDat_V05r_stat.R” to generate one fluorescent intensity 
(FI) value for the peptide-specific IgG response from the tripli-
cates. Individual IgG responses were mapped using the R-script 
“MapAlign_BG_V11.R” after subtraction of FI values from 
baseline plasma. The array included the immunogen sequence 
CN54gp140 and nine other sequences from acute phase primary 
HIV isolates of subtypes A, C, B, CRF01_AE, and CRF02_AG 
to maximize coverage of global HIV diversity (Ahmed et al., in 
preparation).
statistical analyses
All clinical and routine laboratory data were included in the 
safety analyses. Data sets included (i) modified intention to 
treat; all participants who were randomized and received at 
least one vaccination and (ii) per protocol (PP), all participants 
who completed vaccinations with no major protocol deviations. 
The primary safety outcome was expressed as a proportion of 
participants with 95% confidence interval, and groups were 
compared using Fisher’s exact test. The primary immunologi-
cal outcome was the magnitude of serum CN54gp140-specific 
IgG 4 weeks after the final vaccination and we assumed a 100% 
response rate in the standard (reference) arm. The sample size 
was calculated on the basis of the binding antibody responses 
distributions described in the RV144 trial. In this trial, the 
reciprocal GMT of binding antibodies to subtype E gp120 was 
~1:15,000 (log10: 4.18) and for subtype B gp120 was ~1:30,000 
(log10:4.5). On the basis of previous trials, we assumed that 
everyone would respond to the CN54gp140 and that the titer of 
subtype C-specific binding antibody responses would be in the 
same range and at least 1:15,000 in the standard group and that 
a four-fold increase in the magnitude of would be immunologi-
cally relevant. This translates to an absolute difference of 0.6 on 
the log10 scale. In the absence of raw data from the Rv144 trial, 
we have assumed a standard deviation of 0.58 on the log 10 scale 
in the distribution of the antibody responses (corresponding to 
a SD of ~33,400 in titer). Assuming this variation, 20 partici-
pants per group allowed for the detection of an absolute increase 
in titer of 0.60 with 90% power and 5% alpha. Comparison of 
the groups was made using the geometric mean (GM) ratios 
of the titer with their 95% CI and equality was assumed if 
these ratios included 1. Skewed data was log transformed for 
normality and then comparisons made using parametric tests. 
Secondary outcomes were compared by the response frequency 
per group, using chi-square tests if frequencies were adequate or 
the Fisher’s exact 2-tailed test for small numbers. Comparison 
of the magnitude of T-cell ELISpot responses was made using 
the non-parametric Wilcoxon two-sample test. No corrections 
were made for multiple testing. For the flow cytometric analy-
sis, responses are described relative to each mock-stimulated 
control. Two-by-two contingency tables were generated to com-
pare the peptide stimulated versus the mock control for each 
cytokine and T-cell subset. One-sided Fisher’s exact tests were 
then applied to each table to resolve whether the percentage of 
cytokines generated following peptide stimulation was greater 
than that compared following stimulation with mock antigen. 
Bonferroni corrections were applied to account for multiple 
testing. Heatmaps summarizing ICS analyses were generated 
using SPICE version 5.1 downloaded from http://exon.niaid.
nih.gov (41).
resUlTs
Participant accrual, study Population, and 
compliance with schedule
Of 75 healthy, low-risk, HIV-negative volunteers screened 
between 19th June 2013 and 10th January 2014, 40 were enrolled; 
the reasons for the 35 who were screened out are summarized in 
Figure 1. Twenty participants were enrolled at each center, and 
baseline characteristics are summarized in Table 2. The majority 
were white, half were female and the median age was 32 years 
(IQR 23–39). All randomized participants received the first 
immunization but two in the standard group did not complete 
the immunization schedule due to adverse events. In addition, 
two participants from the standard group missed the final visit 
at weeks 40 and 1 also missed the primary immunogenicity 
endpoint visit at week 32 (Figure 1).
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Primary safety endpoints
Four (20%; 95% CI 5.73–43.66) participants in the standard 
group and one (5%; 95% CI 0.13–24.87) participant in the accel-
erated group experienced a primary safety endpoint, p = 0.342 
(two-tailed Fisher’s exact test). Two of these were ≥grade 3 
laboratory adverse events that resulted in discontinuation of vac-
cinations. Both occurred in males aged 20 years in the standard 
group. The first occurred after the first DNA; the 7-day blood 
test revealed asymptomatic transaminitis (AST 375: Grade 3, ALT 
109: Grade 2), which was confirmed 6  days later. Other blood 
tests, a viral screen, and ultrasound scan were normal. Apart 
from an episode of tonsillitis between screening and enrollment, 
treated with penicillin V, there were no other risk factors. The 
levels spontaneously returned to normal during the following 
week, but due to the temporal nature, a relationship could not be 
excluded and so vaccinations were discontinued. The second case 
occurred after administration of the second MVA-C. In between 
the immunization visit and the safety review, the participant 
reported an episode of vomiting after drinking around 12–14 
units of alcohol, and strenuous exercise. The 7-day blood test 
revealed a transaminitis (AST 530: Grade 4, ALT 184: Grade 2). 
He was not able to return for 28 days at which time both were 
within the normal range. investigations including an ultrasound 
scan and blood tests for causes of viral and non-viral hepatitides 
were normal. Although it was felt that the more likely cause of the 
transaminitis was a combination of unusually high alcohol intake 
and strenuous exercise, there was a temporal relationship with 
vaccination and so vaccinations were discontinued. There were 
five others ≥grade 3 adverse events reported by three participants 
on diary cards during the 7 days after vaccination: severe malaise 
in a female accompanied by a headache 2  days after the first 
MVA-C/CN54gp140 GLA-AF, severe malaise in a male 5  days 
after the first CN54gp140 GLA-AF, and a severe/extreme lumpy 
swelling in a female 6 days after receipt of the first MVA-C and 
then again 3 and 6 days after the second MVA-C reported by the 
same participant.
There was one serious adverse event during the study; a female 
randomized to the accelerated group was referred to hospital by 
her GP with pain and suspected appendicitis 2 days after receiving 
her first combined MVA-C and CN54gp140 vaccination. She was 
treated with paracetamol for the pain (moderate grade according 
to the toxicity table) before being discharged after an overnight 
stay when the pain had resolved. The participant continued in 
the trial and received her last immunization without a repeat of 
this problem.
Other adverse events
All of the remaining solicited local, systemic and other events 
were mild or moderate. There were 10 laboratory abnormalities 
other than those reported above, all of these were mild (5 raised 
ALT, 3 AST, 1 hyperglycaemica, and 1 bilirubin). There were dif-
ferences in reporting between the centers (125 by Surrey; 50 by 
Imperial) and by gender (119 by females; 56 by males).
immunogenicity
All analyses presented below are derived from the PP data set and 
include 20 from the accelerated group and 17 from the standard 
group unless otherwise stated (1 participant from the standard 
group who received all vaccinations did not attend the primary 
immunogenicity visit and 2 did not receive all vaccinations).
Primary immunogenicity endpoint
CN54gp140-Specific Binding Antibody
At the primary endpoint 4 weeks after the final vaccination, all 
individuals who completed the schedule made CN54gp140-
specific IgG. The GM titer and concentration of specific binding 
antibody in the accelerated group at the primary endpoint were 
6,424 (95% CI 4,391–9,396) and 10.46 µg/ml (95% CI 7.3–15.0) 
and in the standard group 6,578 (95% CI 3,927–11,020) and 
12.76  µg/ml (95% CI 8.7.0–18.75), respectively. There was no 
significant difference between the groups; as assessed by the ratio 
of the GM titer (0.98, 95 CI 0.53–1.79, p = 0.93) or concentration 
(1.46, 95% CI 0.49–4.34, p = 0.49). The response was first detected 
in both groups 4 weeks after the first MVA-C (week 20) when 
15/20 (75%) in the accelerated and 8/18 (44.4%) in the standard 
group were positive—with a greater response in the acceler-
ated group, p =  0.02. In both groups, the response increased 
significantly after each subsequent vaccination (Figure  2). In 
the accelerated group, the GMT at week 20 was 517, and this 
increased to 6,424 at week 24. In the standard group, the GM 
titer was 17 at week 20, increasing to 246 at week 24, 3,596 at week 
28, and 6,578 at week 32. In both groups, the response fell away 
again by week 40; to GMT 1,302 and 2,536 in the accelerated and 
standard groups, respectively, a difference which was significant 
(p = 0.02) (Figure 2). There was no CN54gp140-specific serum 
IgA detected at any time point.
Mucosal Antibody Responses
Of the mucosal sites sampled, CN54gp140-specific IgG was only 
detected in cervicovaginal secretions, with no specific responses 
detected in either urethral or rectal samples (Figure  3). The 
only samples included in the analyses of mucosal secretions 
were collected from women using Instead cups. There was no 
CN54gp140-specific IgG detected in samples at baseline, and at 
the primary endpoint there was no difference in the frequency of 
responders between the groups; 70% (7/10) women had detectable 
CN54gp140-specific IgG in the accelerated group as compared to 
88% (7/8) in the standard group (p = 0.59, Fisher’s exact test). The 
GM concentration of cervicovaginal CN54gp140-specific IgG was 
0.11 µg/ml (95% CI 0.01–1.28) in the accelerated group compared 
with 0.43 µg/ml (95% CI 0.05–3.7) in the standard group 4 weeks 
after the final vaccination. There was no CN54gp140-specific IgA 
detected in cervicovaginal samples.
Neutralizing Antibody Responses
Neutralizing antibody responses were detected against two Tier 
1A Env-pseudoviruses (Figure 4). At the primary endpoint 9/20 
(45%) participants in the accelerated group showed neutraliza-
tion of subtype C MW965.26 virus (closest match to CN54gp140) 
compared to 14/17 (82%) in the standard group, a difference 
which was statistically significant (p = 0.04, Fisher’s exact test) 
with higher median titer neutralization in the responders from 
the standard relative to the accelerated group (median titer of 
51 and 78, respectively). There was also a trend toward a higher 
FigUre 4 | serum neutralizing antibody responses by group. 
Neutralizing antibodies measured in serum from accelerated and standard 
groups at the primary endpoint, 4 weeks after the final vaccination: 
accelerated group, closed black circles (measured at week 24) and  
standard group, closed red circles (measured at week 32). Virus strains; 
MW965.26 (Clade C, Tier 1A), MN.3 (Clade B, Tier 1A), 00836-2.5 (Clade C, 
Tier 1B), ZM197M-PB7 (Clade C, Tier 1B), Ce1176_A3 (Clade C, Tier 2), 
Ce703010217_B6 (Clade C, Tier 2), and HIV-25710-2.43 (Clade C, Tier 2). 
Solid lines represent geometric mean titer with 95% CI. The frequency of 
responders in each group was compared using the Fishers exact test, 
*p = 0.04.
FigUre 3 | Mucosal binding cn54gp140-specific binding antibody 
responses by group. Concentrations of CN54gp140-specific cervicovaginal 
IgG responses at the primary endpoint at week 24 for accelerated (black 
circles) and week 32 for standard groups (red circles) and at week 40 for 
both. Solid lines represent geometric mean (GM) values with 95% CI. 
Comparisons were made using non-paired t-tests using GM values, and 
there were no significant differences between the groups.
FigUre 2 | serum cn54gp140-specific binding antibody responses 
by group. CN54gp140-specific serum IgG responses in accelerated (black 
closed circles) and standard groups (red closed circles). Solid lines represent 
geometric mean (GM) values with 95% CI. Comparisons made using the GM 
ratio of titers and concentration by group at the primary endpoint, and there 
were no significant differences between the groups (comparison of week 24 
for accelerated group and week 32 for standard group).
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frequency response to MN.3 (Tier 1 subtype B) in the standard 
group (10 versus 35% positive, p = 0.107). There was no neutrali-
zation detected against two Tier 1B Clade C viruses (00836-2.5, 
ZM197M-PB7) or against 2 Tier 2 clade C viruses (Ce1176_A3, 
Ce703010217_B6, HIV-25710-2.43).
Peptide Array Mapping of the Env-specific Antibody 
Response
Vaccine-induced Env-specific IgG responses to linear 15-mer 
peptides (Table 3) were mapped using a custom designed peptide 
micro array approach in subjects of accelerated group (n = 12) 
and standard group (n = 11) 4 weeks after the final vaccination. 
The immunodominant regions (IDRs) targeted and magnitude 
of region-specific responses were largely similar between the two 
groups (Figure 5). IDRs were exlusively located within gp120 with 
little recognition of gp41. Basic characteristics of IDR-specific 
IgG responses including the representative peptide sequence 
targeted and mean fluorescence intensity within each group are 
summarized in Figure 5. Within gp120, four consecutive peptides 
covering the tip of the V3 region (indicated as peak 5, aa300 to 
320 (HxB2 reference strain) were targeted by >90% of vaccinees 
with a high mean fluorescence intensity (MFI) (referring to the 
highest measured response, if multiple peptides covered for this 
region) of above 50,000 units in both groups. Other IDRs were 
located in the C1 region (peak 1; HxB2 aa position 104–124 and 
peak 2; HxB_aa117–136) with maximum MFIs of 43,000 and 
25,000 in standard and accelerated groups, respectively; in the 
FigUre 5 | specificity of systemic binding antibody responses to env by group. Frequency of recognition of linear overlapping peptides spanning the HIV 
envelope in plasma samples from the accelerated (n = 12, upper panel) and the standard groups (n = 11, lower panel). The y axis shows the proportion of 
individuals recognizing the specified peptides and the x axis denotes the distribution of linear peptides along the envelope with relevant regions of interest 
highlighted.
Table 3 | antigenic peaks of recognition in env.
Peak number hXb2 env region representative sequence MFi standard MFi accelerated
1 104 C1a MHEDIISLWDQSLKP 34650 19507
1 107 C1a DVISLWDQSLKPCVK 43478 25183
1 109 C1a ISLWDQSLKPCVKLT 41274 21634
2 119 C1b/V1 SVKLTPLSVTLNSTD 11993 x
2 121 C1b/V1 KLTPLCVTLNCTNAK 29195 x
3 200 C2 AITQACPKVTFDPIP 30593 25445
4 245 C2 VQCTHGIKPVVSTQL 33780 36173
4 249 C2 HGIKPVVSTQLLLNG 15699 20643
5 300 V3 GNNTRKSIRIGPGQT 44475 40678
5 301 V3 NNTRKSIHIGPGQAF 60570 59711
5 304 V3 RKSINIGPGRAFYAT 59915 59186
5 305 V3 TSIRIGPGQTFYATG 59589 56526
6 429 C4 EVGKAMYAPPIKGQI x 15762
6 433 C4 AMYAPPIKGQIKCLS x 19922
7 473 C5 GDMRNNWRSELYKYK 34577 22160
7 475 C5 MKDNWRSELYKYKVV 37522 22782
8 491 C5 IKPLGVAPTTTKRRV 35026 35758
Summary of HxB location, Envelope region, representative peptide sequences, and mean fluorescence intensity (MFI) of the most frequently recognized antigenic regions in Env 
displayed in Figure 5 and the MFI of each peak from standard (n = 11) and accelerated (n = 12) groups.
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C2 region (peak 3; HxB_aa200–215 and peak 4; HxB_aa245–264) 
with MFIs between 25,000 and 35,000; and in the C4 (peak 6 
HxB2_aa429–457) and C5 regions (peak 7, HxB2_aa473–490 
and peak 8, HxB2_aa491–504) were targeted with MFIs between 
20,000 and 38,000. All these IDRs were recognized by 70% of 
vaccines in at least one group. There was no significant differ-
ences between the groups in terms of the number of epitopes 
recognized, the magnitude of individual responses or the sum of 
fluorescence intensity values for all peptide variants recognized 
that were included in the array (p = 0.21).
FigUre 6 | T-cell elispot responses by group over time to vaccine encoded peptide pools. Distribution of IFNγ ELISpot responses (background 
subtracted; spot forming units per million PBMCs) prior to and following vaccine candidate administration for six HIV-1 peptide pools; CN54 1/2, Env 1 (a) and 2 
(b), ZM65 Gag (c), Nef (D), 5′ Pol (e), and 3′ Pol (F). Boxes represent the interquartile ranges, whiskers extend to the 5th and 95th percentiles and the green bar is 
the median. Red circles represent positive responses, black circles are negative responses. Accelerated group: open boxes, n = 20, Standard group: orange boxes, 
n = 18. Dashed line is the ELISpot assay positive response value (38 SFU/million PBMCs).
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T-Cell ELISpot Responses
There were no IFNγ ELISpot responses at baseline and 8 weeks 
after the third DNA vaccination (week 16) responses were seen 
in a minority of individuals to Env peptide pools (20.5% overall). 
At the primary endpoint, there was no difference in either the 
frequency or magnitude of ELISpot responses between groups; 
85 and 82.4% responded to any pool in the accelerated and 
standard groups, respectively, at the primary endpoint (p = 1.00) 
with overall GM values of 111 and 147 SFC/106 PBMCs (p = 0.44) 
Figure  6. All responding individuals recognized one or both 
Env peptide pools (75.0 and 76.5% recognizing Env pool 1 and 
65.0 and 64.7% recognizing Env pool 2 for the accelerated and 
standard groups, respectively, p values >0.99) and the magnitude 
of these responses was similar between groups [medians 70–189 
SFC/106 PBMCs for the two Env pools (p =  0.09–0.32)]. Gag 
peptide-specific responses were relatively modest and detected 
in only 25% of the accelerated and 23.5% of the standard group 
(p = 1.00) with similar magnitude (median 58 and 86 SFC/106 
PBMCs, p = 0.28). There were no responses to the 5′ Pol pool in 
either group and none of the accelerated group and 17.6% of the 
standard group responded to the 3′ Pol pool (p = 0.09, median 
43 SFC/106 PBMCs). None of the accelerated group and 5.9% of 
standard group responded to Nef peptides (p = 0.46, 1 response 
of 179 of SFC/106 PBMCs in the standard group). At this time 
point, the mean number of peptide pools recognized (out of a 
total possible of 6) for each subject was similar between groups; 
1.65 and 1.88 for the accelerated and standard groups respectively 
(median of 2 for both groups, p = 0.63). In terms of magnitude, 
responses to Env pools peaked 4 weeks after the second MVA-C/
CN54gp140 (median 111 SFC/106 PBMCs) in the accelerated 
group and 4 weeks after the first MVA-C in the standard group 
(median 213 SFC/106 PBMCs). While the great majority of 
responses in both groups recognized Env or Env plus Gag pep-
tides, recognition of ENV in combination with Nef or 3′Pol or of 
Gag peptides was only seen in the standard group—accounting 
for approximately 17% of all responses (data not shown). In the 
FigUre 7 | heatmaps showing the frequency of different cytokine responses by T-cell subset over time by group. Overall frequency of different 
combinations of three cytokines (IFNγ, IL2, and TNFα) produced by CD4 (a) and CD8 (b) T-cells responses to combinations of P5/6 Env peptide pools by week. 
The highest frequency (% of total) is shown in red and the lowest in blue (scale depends on maximal response). Due to the low frequency of responses, no formal 
statistical comparisons were made between the groups.
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accelerated group, responses to Env and Gag peptides dropped 
between weeks 24 and 40 (p = 0.04, 0.02) whereas in the standard 
group there was no significant change (p = 0.4, 0.65). At week 
40, the responses to Env and Gag peptide pools was of greater 
magnitude in the standard than the accelerated group (p = 0.03, 
0.02, and 0.091, respectively) and more frequent to Env peptides, 
with 71% responding to both Env peptide pools in the former 
compared to 37 and 47% in the latter (p =  0.09 for responses 
to Env 1 pool) and this was also true of responses to Gag pep-
tide pools with 30% responding in the standard and 5% in the 
 accelerated group.
Intracellular Cytokine Responses
Overall, intracellular cytokine responses were modest and 
results are therefore descriptive. The majority of responses were 
polyfunctional and focused toward Env rather than Gag peptide 
pools. Response rates to any antigen at any post-baseline visit, 
for both CD4 and CD8 populations, were higher in the standard 
than the accelerated group, 50 versus 30% respectively for CD4+, 
and 33.3 versus 10% for CD8+ lymphocytes, but these differences 
were not statistically significant (data not shown). CD4 and CD8 
responses to all antigens were predominantly polyfunctional, 
with IFNγ being the dominant cytokine (Figure 7). The standard 
group tended toward higher CD8 responses (IFNγ+TNFα+) 
while both groups had comparable CD4 responses (the majority 
being IL2+IFNγ+). In the standard group, responses seemed to 
peak at week 24 and wane at week 32 in CD4 lymphocytes but 
were more persistent in some CD8 lymphocytes (data not shown).
DiscUssiOn
We have compared two vaccination regimens using identical 
DNA-C, MVA-C, and GLA adjuvanted CN54gp140 with the aim 
of assessing the safety and immunogenicity of a shortened regi-
men in which the MVA and adjuvanted protein were combined. 
We expected strong Env-specific CD4+ T-cells after DNA and 
MVA and Env-specific binding antibodies in everyone after 
adjuvanted gp140 and the study was powered to detect a four-fold 
difference in the magnitude of this response between groups. As 
expected, 100% individuals made strong CN54gp140-specific 
antibody irrespective of regimen, but combining the vaccines 
had no detectable impact on the magnitude or specificity of 
the antibody response as assessed by the recognition of linear 
peptides. This pattern was characterized by strong recognition 
of V3 with notably little recognition within gp41—in spite of 
its presence in the DNA and gp140 vaccines. The immunogens 
also induced recognition of linear epitopes within C2 and C4, 
but their significance, if any, is unknown. Despite these binding 
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antibody responses, neutralizing antibody responses were disap-
pointing and only seen to Tier 1A pseudoviruses, similar to our 
previous experiences using this adjuvanted protein (27, 28). 
Interestingly, however, the frequency and titer of the responses 
was inferior when vaccines were combined to two Tier 1A pseu-
doviruses. There was no difference in the overall frequency or 
specificity of T-cell ELISpot responses which were seen in >80% 
individuals irrespective of group and tended to be CD4+ and 
specific for Env peptide pools. While the great majority of IFNγ 
ELISpot responses were seen to Env peptide pools in both groups, 
recognition of Gag, Nef and Pol peptides was less frequent in the 
accelerated group suggesting that combining the vaccines might 
have led to further polarization of immune responses. Cytokine 
responses were relatively modest, but also less frequent or less 
polyfunctional in both CD4+ and CD8+ compartments when the 
MVA and CN54gp140 were combined. There was no significant 
impact of combining the vaccines upon tolerability. Although 
two participants experienced events that resulted in discontinu-
ation of immunizations, these followed different immunogens 
(DNA-C, MVA-C) and there were alternative explanations for the 
asymptomatic elevation in transaminases in each case. The great 
majority of adverse events were mild in line with our previous 
experience using the same adjuvanted protein in different settings 
(27, 28).
Even though we controlled for variables such as site and 
gender, the study has limitations; overall statistical power was 
compromised by the fact that we did not have 40 in the final 
analyses as planned. Nevertheless, there was clear evidence that 
combining MVA and gp140 led to attenuation of certain T-cell 
and B-cell immune responses. Both regimens were shorter overall 
than used in previous studies using similar homologous (22–24) 
or heterologous DNA and MVA (26, 42) and it remains possible 
that the time between DNA prime and MVA boost (8  weeks) 
might have been too short to allow for the optimal maturation of 
immune responses. The use of a common and semi-quantitative 
assay for the measurement of CN54gp140-specific IgG antibody 
allows for direct comparison across our different trials. The 
median CN54gp140- specific binding antibody response seen 
here (12.8 µg/ml) exceeds that seen in the Mucovac 2 trial (UK 
HVC_001) after three doses of CN54gp140/GLA-AF IM in the 
absence of DNA priming (4.2  µg/ml) (27), but is lower than 
seen in the TaMoVac 01 trial (UK HVC_00 2) after boosting 
twice with GLA-AF adjuvanted CN54gp140 30–71  weeks after 
priming with DNA and MVA (17.8 µg/ml) (28). This supports 
the value of DNA/MVA priming and suggests that the long 
gap between prime and boost could be important. Sallusto and 
colleagues propose a minimum gap of 12 weeks and note that if 
boosting is too frequent, responding cells might be preferentially 
driven to terminal differentiation resulting in attenuation of 
immunity (43).
Our decision to use immunogens expressing matched sub-
type C inserts was driven by our commitment to a vaccine for 
use in Sub-Saharan Africa as well a belief that this approach 
would ellicit high titer binding antibodies and so favor func-
tional/neutralizing antibodies. In addition to the logistical 
advantages offered by fewer vaccinations, we were interested 
in combining the pox and protein in light of the results of 
the RV144 trial which included combined canarypox and 
alum adjuvanted gp120 and was the first ever trial of an HIV 
vaccine to show (modest) efficacy. In UK HVC_003 overall, 
immunogenicity was somewhat disappointing and it remains 
possible that the combined MVA and adjuvanted gp140 protein 
may have overwhelmed the pool of antigen-specific/innate 
immune cells, as offered as one explanation of the attenuation 
in responses sometimes seen when certain pediatric vaccines 
are combined (44, 45) and which might be particularly associ-
ated with MVA at it has been shown to be highly immunogenic 
and to preferentially deplete antigen presenting cells (46–48). 
Immunogenicity may have been further compromised in the 
accelerated group as a result antigenic competition (even 
though the vaccines were administered into opposite arms) as 
has been suggested to occur in response to response to certain 
combinations of conjugated vaccines (49) and observed more 
recently in an HIV vaccine trial in South Africa (25). The choice 
of adjuvant was partly practical as we had access to GLA-AF 
through the UK HVC and had already used it with the same 
gp140 protein (27, 28). In our hands, the GLA-AF (MPLA) 
adjuvant has previously been shown to be potent for antibodies 
at equivalent (3 ×  100  µg) and lower (3 ×  20  µg) doses (27) 
(in the absence of DNA/MVA), and we had every reason to 
suspect that priming would further enhance these responses. 
We expected the immunogens to be at least as immunogenic as 
those used in RV144 in both groups and, based on our previous 
experiences with DNA and MVA, predicted that they would be 
more potent for T-cells.
In light of these findings, we remain cautious about the 
accelerated regimen, and feel that the combined MVA-C and 
adjuvanted GLA-AF warrants further evaluation in a regimen 
with a longer gap between priming and boost. We believe this 
trial provides further support for exploring the clinical efficacy 
of a priming regimen including DNA, with at gap of least 
12  weeks prior to boosting. The precise contribution of adju-
vanted protein (if any) is yet to be defined. While Churchyard 
and colleagues reported no clear benefit of DNA priming on 
Env-specific antibody responses, T-cell responses appeared 
augmented by the priming although overall immunogenicity in 
the trial was lower than seen previously using the same vaccines 
in a different population (25). In light of our previous experi-
ence with a variety of immunogens, we remain committed to 
the inclusion of DNA as we believe balanced immune responses 
highly desirable. We await data from a direct comparison of the 
specificity of antibody responses from trials using different het-
erologous prime boost regimens (including RV144 and Tamovac 
01) with this one to inform our selection of immunogens to take 
forward. Non-neutralizing IgG antibody responses targeting V2 
have been shown to correlate with a reduced risk of HIV using 
a variety of different approaches, although we did not see much 
response to linear peptides within this region (9, 50, 51) suggest-
ing perhaps that they are associated with the subtype E gp120 
protein. We did however see strong recognition of the V3 loop in 
both groups and this has been described as characteristic of the 
responses seen during natural infection (27) and also in other 
vaccine trials including RV144-when the response correlated 
with reduced risk of HIV acquisition in a subset of individuals 
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(51). In conclusion, the vaccines were potent irrespective of 
regimen, but immunogenicity was lower than anticipated, and 
we cannot exclude the possibility that this was due to the rela-
tively short regimens. Our data suggest that combining MVA 
and CN54gp140/GLA-AF in this relatively short regimen had 
no significant impact on safety and also no impact on the mag-
nitude of CN54gp140-specific systemic antibody responses and 
the strategy may have attenuated immunogenicity as reported 
previously (25).
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Tuberculosis (TB) epidemiology is changing in Western and Central Europe due to the
rise in immigration and refugees fleeing high-TB-burden areas of war and devastation.
The change in local demography and the lack of sensitive and specific TB diagnostic and
monitoring tools, especially for cases of childhood TB, leads to either missed cases or
over-treatment of this group. Here we present a promising new diagnostic approach, the
T cell activationmarker (TAM)-TB assay, and its performance in a case of extra-pulmonary
TB occurring in a 16 year old refugee from Afghanistan. This assay is based on the
characterization of 3 activation markers (CD38, HLA-DR, and Ki67) and one maturation
marker (CD27) on M. tuberculosis-specific CD4T cells. It was performed at time-points
T0 (10 days), T1 (1 month), T2 (6 months), and T3 (12 months) post-treatment initiation.
All markers were able to detect active tuberculosis (aTB) within this patient at T0 and
reverted to a healthy/LTBI phenotype at the end of treatment. Tantalizingly, there was a
clear trend toward the healthy/LTBI phenotype for the markers at T1 and T2, indicating
a potential role in monitoring anti-TB treatment in the future. This assay may therefore
contribute to improved TB diagnostic algorithms and TB treatment monitoring, potentially
allowing for individualization of TB treatment duration in the future.
Keywords: extra-pulmonary tuberculosis, treatment monitoring, TAM-TB assay, TB diagnostics, pediatric
tuberculosis
INTRODUCTION
Childhood TB, particularly in its extra-pulmonary form, is very challenging to diagnose, let alone
to monitor treatment response (1, 2). Predictive markers that would allow clinicians to differentiate
between ongoing active disease and cure as well as specific correlates for protection are lacking (3).
Thus, there is an urgent need for improved diagnostic tests. Traditional diagnostic tests such as
the Tuberculin Skin Test (TST) or the Interferon Gamma Release Assays (IGRAs) are primarily
detecting Mycobacterium tuberculosis (MTB) infection, however their inability to differentiate
between aTB, LTBI and successfully treated TB makes them an unsatisfactory tool for diagnosis
of active TB. Only two diagnostic methods in use form the current “gold standard,” the liquid
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culture method, and the PCR technique (GeneXpert MTB/RIF R©,
Cepheid) both of which involve the detection of MTB in sputum
or other clinical samples. However, the reliance on sputum
samples makes the liquid culture susceptible to contamination
(4). Furthermore, obtaining sputum samples from pediatric
patients, especially in infants, is difficult. Another, group of
patients where microbiological detection of MTB tends to be
difficult consists of extra-pulmonary cases who do not necessarily
produce sputum containing MTB. In addition to the described
sampling issues the liquid culture method is a long process,
requiring weeks for results to be available, Furthermore, a major
limitation of all currently available diagnostic tools is their
inability to monitor treatment response. Liquid culture methods
require weeks for results to be available, and as treatment
progresses the production of sputum and detection of live
MTB in sputum becomes more difficult (5). The GeneXpert
MTB/RIF R© method, though being a very sensitive method is
hampered by its inability to differentiate between live and dead
bacilli, thus not allowing for evaluating success of treatment
(6). This has led to a presumed overtreatment of a majority
of pulmonary TB patients, shown in previous studies reporting
that at least 80% of pulmonary TB patients had been cured
within 4 month of anti-TB treatment not showing any signs
of relapse within the defined study period (7–9). An optimal
monitoring tool would be rapid and dynamic to allow in vivo
measurement of changes of biomarkers to mirror treatment
progress in each individual patient, this opens the avenue toward
a personalized medicine approach in TB care—particularly in
children and adolescents.
AN EXEMPLARY CASE
A 16 year-old male refugee fromAfghanistan with a self-reported
unremarkable past medical history presented to our tertiary care
hospital complaining of a 3 months history of worsening left-
sided hip pain, while otherwise being clinically well without signs
of fever. Four weeks prior to presenting to our institution he had
been seen in a private surgical practice. An ultrasound of the hip
revealed significant effusion and joint fluid aspirate obtained via
subsequent puncture was sent for conventional bacterial cultures.
The patient was discharged home on ibuprofen; conventional
microbiological culture showed no growth of bacteria. On
presentation to our A&E department he was unable to walk due
to severe left-sided hip pain, while being otherwise clinically
well. His routine bloods showed a mildly raised CRP (26 mg/l),
normal FBC and chemistry. Conventional radiography and a
subsequent MRI scan of the left hip showed blurring of cortical
margins of the femoral head and acetabulum, hyper intensity
of the left hip and acetabulum (oedema of the bone marrow)
and marked joint effusion on the T2 weighted image with fat
suppression as well as synovial thickening and enhancement on
the post-contrast T1 weighted image (Figures 1A–C). A chest
x-ray showed signs of adult-type TB, but the patient did not
display any clinical evidence of active pulmonary tuberculosis
(data not shown). Hence, this result was not followed up by a
CT scan of the chest. In view of the prolonged, non-acute clinical
course, and his background of being born and raised in a TB
high-endemic country (national incidence, including HIV+TB:
189 per 100.000; source: http://www.who.int/tb/country/data/
profiles/en/), work-up for suspected tuberculosis of the hip
was initiated. IGRA testing (QuantiFeronGold R©, Qiagen) was
positive; AFBs were seen on microscopy from joint fluid
aspirate, subsequently confirmed asM. tuberculosis (MTB) using
PCR (GeneXpert MTB/RIF R©, Cepheid) and culture. Since we
were able to diagnose this patient on his joint fluid aspirate
(microscopy results available on the same day), we deliberately
refrained from a synovial biopsy, a more invasive diagnostic
approach, generally recommended to obtain the gold standard
specimen if joint involvement is suspected in tuberculosis.
An HIV test was negative. The patient reported that he had
never received any treatment for TB previously. He was started
on isoniazid, rifampicin, pyrazinamide, and ethambutol for
2 months, followed by an additional 10 months period on
rifampicin and isoniazid. Drug resistance testing showed a fully
sensitive MTB isolate. Treatment was well tolerated and during
the 12 months course, the patient showed continuous clinical
improvement with regular ibuprofen required until month 3
of treatment. During this phase, treatment was supplemented
by pantoprazole. Follow-up clinical visits revealed no signs of
side effects and radiological assessment documented gradual
improvement on MRI imaging but also unavoidable long-term
damage to the left hip joint on conventional x-ray in terms
of severe narrowing of the joint space, osteophytes and severe
deformity of the femoral head was evident (Figures 1D,E).
Though the patient was able to move slowly without support
and almost free of pain from month 9 of anti-tuberculosis
treatment, regaining his full range of movement was impossible
due to extensive destruction of the left hip. Thus, almost 2 years
following TB diagnosis he underwent hip-replacement surgery
and is currently in perfect health having regained full mobility.
TAM-TB ASSAY RESULTS
After obtaining written informed consent from the patient, we
tested a novel, rapid, sputum independent diagnostic approach,
now referred to as the T cell activation marker (TAM)-
TB assay. The TAM-TB assay has been shown to accurately
differentiate between active pulmonary TB (aTB) and latent TB
infection (LTBI) in different age groups by determination of the
phenotypic and functional characteristics of MTB-specific CD4T
cells via flow cytometry (10–12); detection of high frequencies
of activated (CD38+, HLA-DR+, and Ki67+), CD27low effector
memory MTB-specific CD4T cells is indicative of active TB.
Furthermore, results using this approach have been shown
to correlate with disease severity and lung tissue destruction
(13). Sequential blood samples were obtained from the time
of diagnosis (T0, day 10 after treatment initiation), 1 month
(T1), 6 months (T2) post-treatment initiation, and at end of
treatment (12 months, T3) in order to determine expression
levels of the T cell activation markers CD38, HLA-DR, and Ki67
and thematurationmarker CD27 on IFNy+MTB-specific CD4T
cells. As previously described (14), the assay was performed
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FIGURE 1 | Initial X-ray of the left hip showed blurring of the cortical margins of the femoral head and acetabulum, slight demineralization, and a bulging fat pad
surrounding the hip suggesting a joint effusion (A). On the initial MRI scans there was a hyper intensity of the left hip and acetabulum (=oedema of the bone marrow)
as well as marked joint effusion on the T2 weighted image with fat suppression (B), synovial thickening and enhancement on the post-contrast T1 weighted image
with fat suppression (C). These MRI findings were receding following 13 months of anti-TB treatment (T2 weighted image with fat suppression, D) on the one hand,
but on the other hand a severe narrowing of the joint space, osteophytes and severe deformity of the femoral head became present. These findings of secondary
osteoarthrosis were also demonstrated on the follow-up X-ray few months later (E).
by stimulation of PBMCs with ESAT-6/CFP-10, PPD, and
Staphylococcal enterotoxin B (SEB), as a positive control, or
no added peptide, as a negative control. PBMCs were surface
stained with anti-CD4, anti-CD38, anti-CD27, and anti-HLA-
DR, fixed and permeabilized, then stained intracellularly with
anti-CD3, anti-IFNy, and anti-Ki67. Data from subjects with
active pulmonary TB and LTBI from our previous study to define
the cut-offs for each marker to differentiate aTB and LTBI were
used (14). Remarkably, at T0 all four markers assessed in the
TAM-TB assay classified our patient as aTB, while at T3 they
showed a similar phenotype to the healthy IGRA+ group of
patients, confirming its potential use in the diagnosis of extra-
pulmonary TB (Figure 2). For ESAT-6/CFP-10 stimulated cells,
the frequency of activated MTB-specific CD4T cells expressing
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FIGURE 2 | Marker expression on MTB-specific CD4T cells. Values are provided at the start, during and at the end of treatment. Frequency of ESAT-6/CFP-10
stimulated MTB-specific CD4T cells expressing the markers CD38 (A), CD27 (B), HLA-DR (C), Ki67 (D), and PPD stimulated MTB-specific CD4T cells expressing
CD38 (E), CD27 (F), HLA-DR (G), Ki67 (H) are displayed as red dots at 10 days (T0), 1 month (T1), 6 months (T2), and 12 months (T3) after TB treatment initiation;
data from subjects with acute pulmonary tuberculosis and healthy/latent TB infection were included as reference (box and whisker plots). Red area represents the
region considered to show an active TB profile with cut-offs based on ROC analysis; ROC cut-off values for ESAT-6/CFP-10, CD38 = 44.9, CD27 = 22.1, HLA-DR =
33.15, Ki67 = 2.43 and for PPD, CD38 = 31.55, CD27 = 18.35, HLA-DR = 35.7, Ki67 = 3.67 (14).
CD38 and HLA-DR declined rapidly within the first month
after treatment initiation from 51.4% at T0 to 24.3% at T1 and
from 49 to 31.6%, respectively (Figures 2A,C). Unlike the other
two markers (CD27 and Ki67), these markers seem to have
provided an LTBI phenotype within a short period (1 month).
The frequency of MTB-specific CD4T cells expressing the cell
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cycle marker Ki67 showed a gradual decrease and was still
within the range observed for aTB at T2 post-treatment, but
eventually indicated “LTBI or cure” at the end of treatment (T3)
(Figure 2D). A substantial increase in the frequency of CD27+
MTB-specific CD4T cells was only observed between T2 and
T3 (Figure 2D). It is particularly noteworthy that at the end
of treatment (T3), the patient showed a TAM-TB assay profile
consistent with “LTBI or cure” for all four markers. Unlike the
ESAT-6/CFP-10 stimulated cells, the frequency of activated PPD
stimulated MTB-specific CD4T cells expressing the activation
markers showed the strongest percentage decline between T2
and T3 (Figures 2E–H). Two of the markers (CD27 and CD38)
seem to show a borderline LTBI phenotype at T2, with all the
markers indicating an “LTBI or cure” at the end of treatment (T3)
(Figures 2E–H).
Future studies will be needed to determine whether TAM-TB
assay results could have guided earlier discontinuation of anti-
TB therapy in patients before the defined 12 months period. Of
note, an additional TAM-TB result obtained from the patient 2
months after discontinuation of anti-TB treatment (14M) was
still consistent with “LTBI or cure” (data not shown).
DISCUSSION/CONCLUSION
Central and Western Europe, Germany in particular, has seen
an increase in TB incidence rate in recent years changing
from 5.2/100.000 (2012) to 7.2/100.000 (2015) (15). This change
in epidemiology has primarily been attributed to an increase
in migration activity from low/intermediate-income, high TB
burden settings as a consequence of people fleeing areas of war
and devastation. Reactivation of latent tuberculosis infection
(LTBI) in the high-income, low TB burden countries has thus
become a challenge for clinicians both in adult and pediatric
care (16). The adolescent case described in this report is a
perfect example of how wildly adapted national diagnostics and
treatment guidelines are often limited in the way they are tailored
to the local population. Almost any youth of German descent
presenting with a painful left hip would have most likely been
diagnosed and treated sufficiently according to those guidelines.
But pediatric or adolescent tuberculosis, especially in its extra-
pulmonary form, is such a rare event in the German setting, that
this differential diagnosis was missed initially. It is important
to highlight the changes in TB epidemiology and to be aware
of TB in patients having moved to central Europe from high
TB burden settings. Although a good outcome was achieved
following hip replacement, this still remains a problematic long-
term solution in someone who is 16 years of age and will
inevitably be requiring additional revision-interventions in the
future. This again underscores the importance of early accurate
diagnosis and treatment.
With this perspective we aim to highlight that the TAM-TB
assay is a promising new tool with great potential to improve
TB diagnostics, particularly in difficult-to-diagnose cases of
extra-pulmonary TB or children and adolescents in whom
conventional tests are frequently unsuccessful. Immunological
biomarkers have already demonstrated to be very promising to
indirectly diagnose TB; and they are highly likely to play an
even more prominent role in TB diagnostics in the years and
decades to come (3, 17, 18). Several studies have shown the
benefit of using flow cytometric techniques to distinguish aTB
from LTBI, the earliest reporting the CD27 marker (19). This was
followed by a plethora of markers such as HLA-DR, CD38, Ki67,
or caspase-3 (12, 20). Other methods using cytokine secretion
in whole blood may allow diagnosis of aTB (21), however these
methods do not seem to be reliable in monitoring TB treatment
(22). Another approachmakes use of whole blood transcriptional
profiling to identify diagnostic RNA signatures for aTB and
LTBI, respectively (2, 23, 24). These studies are extremely
interesting and yielded very promising results. However, they
have not been shown to be of use for treatment monitoring.
Furthermore, until the respective diagnostic signatures have been
transformed into a simpler diagnostic test that could be used
in daily routine, their use appears impractical due to the highly
sophisticated resources required (i.e., running microarrays or
RNA sequencing).
Sali et al. was able to show that combined use of the
QuantiFeronGold R© with a heparin-binding hemagglutinin
antigen (HBHA)-based IGRA helped to differentiate
Quantiferon-positive children with LTBI from those with aTB
(25). While further validation on larger cohorts of MTB-infected
children will be necessary to describe the potential of this method
for treatment monitoring, issues in identifying asymptomatic
children with aTB appears to be its main disadvantage.
In flow cytometry-based assays it has been noted that while
CD38, HLA-DR, and Ki67 appeared to be useful markers
for monitoring of treatment response in a pulmonary TB
cohort; CD27 was a marker that converts rather slowly
to its “healthy” state (12, 19). Our assay was successful
in diagnosing this case of active extra-pulmonary TB and
showed an accurate treatment response at the end of the
12 months treatment period by indicating a “healthy/LTBI”
state reflected in respective expression values for all four
markers. In addition, all markers (with the exception of HLA-
DR in the PPD stimulation assay) did indicate a dynamic
trend toward the desired treatment outcome. Whether and
how such TAM-TB results during anti-TB treatment could
potentially inform decisions on treatment discontinuation in
individual patients in the future remains to be evaluated in
larger cohorts. Since our patient was 16 years of age and because
adolescent children essentially behave like adults, this promising
test will also have immediate relevance to adults with extra-
pulmonary TB.
However, the TAM-TB assay remains an expensive technique
requiring specialized equipment and trained personnel to
operate, thus its use as a point of care test (POCT, on-site)
technique is currently not feasible. However, several studies have
shown that flow-cytometry-based assays can be further simplified
by using whole blood rather than PBMC, thus reducing the
blood volume required and, in consequence, making them more
feasible to use, especially in infants and younger children (26, 27)
Nevertheless, our results provide a first important proof-
of-concept that the TAM-TB assay might also be a useful
and powerful tool to monitor clinical response to treatment
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in cases of extra-pulmonary TB. Though the results of this
case look promising, they only represent the treatment course
of a single patient and one needs to be aware that the
respective values of the four TAM-TB markers were referenced
to cut-off values obtained from a pulmonary TB cohort. It
is likely that since extra-pulmonary TB is a different clinical
entity than the pulmonary form of TB, adjusted cut-offs may
be required for extra-pulmonary TB cases to allow more
accurate interpretation of the results. We do not propose
using the TAM-TB assay as a new stand-alone technique
for diagnosing tuberculosis, but instead we rather suggest to
develop a diagnostic algorithm involving all currently available
tools in order to be able to eventually tailor TB treatment
duration for individual patients. Still, we are confident that
this new assay holds a great potential for the challenging
area of TB care and larger prospective clinical trials are
currently underway to further validate its performance in
the field.
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